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Gerald F. Watts,7 Jan Bore´n,8 Hannsjörg Baum,9 Eric Bruckert,10 Alberico Catapano,11
Olivier S. Descamps,12 Arnold von Eckardstein,13 Pia R. Kamstrup,14 Genovefa Kolovou,15
Florian Kronenberg,16 Anne Langsted,14 Kari Pulkki,17 Nader Rifai,18 Grazyna Sypniewska,19 Olov Wiklund,8
and Børge G. Nordestgaard,14 for the European Atherosclerosis Society (EAS) and the European Federation
of Clinical Chemistry and Laboratory Medicine (EFLM) Joint Consensus Initiative
BACKGROUND: The European Atherosclerosis Society–
European Federation of Clinical Chemistry and Laboratory
Medicine Consensus Panel aims to provide recommenda-
tions to optimize atherogenic lipoprotein quantification for
cardiovascular risk management.
CONTENT: We critically examined LDL cholesterol, non-
HDL cholesterol, apolipoprotein B (apoB), and LDL
particle number assays based on key criteria for medical
application of biomarkers. (a) Analytical performance:
Discordant LDL cholesterol quantification occurs when
LDL cholesterol is measured or calculated with different
assays, especially in patients with hypertriglyceridemia
175 mg/dL (2 mmol/L) and low LDL cholesterol con-
centrations 70 mg/dL (1.8 mmol/L). Increased lipo-
protein(a) should be excluded in patients not achieving
LDL cholesterol goals with treatment. Non-HDL cho-
lesterol includes the atherogenic risk component of rem-
nant cholesterol and can be calculated in a standard non-
fasting lipid panel without additional expense. ApoB
more accurately reflects LDL particle number. (b) Clinical
performance: LDL cholesterol, non-HDL cholesterol, and
apoB are comparable predictors of cardiovascular events in
prospective population studies and clinical trials; however,
discordance analysis of themarkers improves risk prediction
by adding remnant cholesterol (included in non-HDL cho-
lesterol) and LDL particle number (with apoB) risk compo-
nents to LDL cholesterol testing. (c) Clinical and cost-effec-
tiveness: There is no consistent evidence yet that non-HDL
cholesterol-, apoB-, or LDL particle-targeted treatment re-
duces the number of cardiovascular events and healthcare-
related costs than treatment targeted to LDL cholesterol.
SUMMARY: Follow-up of pre- and on-treatment (measured
or calculated) LDL cholesterol concentration in a patient
should ideally be performedwith the same documented test
method. Non-HDL cholesterol (or apoB) should be the
secondary treatment target in patients with mild to moder-
ate hypertriglyceridemia, in whom LDL cholesterol mea-
surement or calculation is less accurate and often less
predictive of cardiovascular risk. Laboratories should re-
port non-HDL cholesterol in all standard lipid panels.
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Measurement of LDL cholesterol (LDLC)20 is a key
component in the assessment of risk of cardiovascular
disease (CVD) and the management of dyslipidemia (1–
4). Indeed, the causality of LDL particles in the patho-
physiology of atherosclerotic CVD is indisputable (5 ).
Furthermore, there is a direct graded relationship be-
tween LDLC concentration and the incidence of CVD
observed in randomized controlled trials and metaanaly-
ses (5, 6 ). All guidelines concur that lowering LDLC to
concentrations below a target of 70 mg/dL (1.8 mmol/L)
(or by 50% if this target cannot be attained) is of crit-
ical importance in subjects at high or very high risk of
CVD (1–4).
Despite the overwhelming evidence that LDLC-
targeted strategies effectively reduce CVD, there is sub-
stantial between-subject variability in the response to
lipid-lowering therapies and the reduction of CVD risk
(7 ). Furthermore, accumulating evidence indicates that a
focus solely on the assessment andmanagement of LDLC
is not an optimal strategy for all patients, in part as emerg-
ing evidence has established that VLDL, their remnants,
and lipoprotein(a) [Lp(a)] likewise are causally related to
CVD (8–11). Major concerns equally relate to the po-
tential for substantial errors in risk estimation given rec-
ognized LDLC measurement or calculation errors in pa-
tients with moderate or marked hypertriglyceridemia or
low LDLC concentrations (Table 1). Clearly, additional
biomarkers beyond LDLC are needed to identify and
treat more persons at high CVD risk, especially in this era
of novel therapies, such as proprotein convertase subtili-
sin/kexin type 9 (PCSK9) inhibition, which efficaciously
target and reduce concentrations of atherogenic lipopro-
tein particles to unprecedented low levels (11, 12 ).
For many years, the inaccuracy in measured or cal-
culated LDLC could be tolerated because of limited clin-
ical impact at the average to high LDLC range. However,
this issue must be readdressed in the contemporary treat-
ment era, in whichmuch lower LDLC concentrations are
seen (12 ) and moderate hypertriglyceridemia is poten-
tially a greater problem because of the increasing preva-
lence of obesity, metabolic syndrome, and diabetes mel-
litus (13, 14 ). Furthermore, limitations of direct LDLC
assays depend on the type of assay. Despite the wide-
spread belief that direct LDLC measurements are stan-
dardized and unequivocal, data indicate that results can
vary significantly between different assays from different
manufacturers (15 ). Difficulties encountered with HDL
cholesterol (HDLC) assays also raise concerns about the
reliability of calculated LDLC and non-HDLC, as HDLC
is used in both calculations (15).
20 Nonstandard abbreviations: LDLC, low-density lipoprotein cholesterol; CVD, cardiovas-
cular disease; Lp(a), lipoprotein(a); PCSK9, proprotein convertase subtilisin/kexin type
9; HDLC, high-density lipoprotein cholesterol; LDLP, LDL particle number; apoB, apoli-
poprotein B; CBR, consensus-based recommendation; dLDLC, direct LDL cholesterol
measurement; cLDLC, calculated LDL cholesterol; TC, total cholesterol; TG, triglycerides;
LPL, lipoprotein lipase; CETP, cholesteryl ester transfer protein; CHD, coronary heart
disease; IDL, intermediate-density lipoprotein; Remnant-C, remnant lipoprotein cho-
lesterol; NMR, nuclear magnetic resonance; KIV-2, kringle IV type 2; CRMLN, Choles-
terol Reference Method Laboratory Network; dHDLC, direct HDL cholesterol measure-
ment; NCEP, National Cholesterol Education Program; EQA, external quality
assessment; VLDLC, very low-density lipoprotein cholesterol; HR, hazard ratio; RR, rel-
ative risk; MESA, Multi-Ethnic Study of Atherosclerosis; VLDLP, VLDL particle number;
OR, odds ratio.
Table 1. Current challenges for LDLC quantiﬁcation.
Cause Problem Recommendationa
Analytical
Novel therapies: very low LDLC
concentrations
Magniﬁcation of measurement and
calculation errors (e.g., Friedewald)
CBR2, CBR3, CBR4
Nonfasting lipid testing Postprandial variation of TG in LDLC
calculation
CBR4, CBR5
Increasing prevalence of obesity, diabetes,
and moderate or major increases in TG
Nonspeciﬁcity bias in hypertriglyceridemic
(>175 mg/dL; >2 mmol/L) and
dyslipidemic samples
CBR2, CBR3, CBR4, CBR9,
FR1, FR2
High Lp(a) Overestimation of LDLC CBR10
Clinical
Increasing prevalence of obesity and
diabetes
LDLC is a less predictive marker CBR1, CBR5, CBR6, CBR7,
FR3
Residual (on-treatment) CVD risk Residual risk unexplained by LDLC CBR8, FR3, FR4
Personalized medicine LDLC has low or no diagnostic and
predictive performance in certain
patients
CBR1, CBR8, FR4, FR5
a CBR and future research recommendation (FR) to address the problem, listed in Table 2 (CBR) and Table 8 (FR).
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In addition to analytical limitations, there is clinical
concern regarding the failure to prevent a large propor-
tion of CVD events that occur despite aggressive LDLC-
targeted statin therapy. Many individuals experience
CVD-related events or progression of atherosclerosis de-
spite having optimal LDLC even at concentrations70
mg/dL (16 ). This residual or “hidden” risk—not identi-
fiable by LDLC—contributes substantially to CVD-
related morbidity and mortality and underscores the
need for a personalized medicine approach using addi-
tional markers to better understand and manage interin-
dividual heterogeneity (17, 18 ). These markers include
LDL subclasses and particle concentration (LDLP), apo-
lipoprotein B (apoB) and mass spectrometry-based pro-
teomics, non-HDLC, remnant cholesterol and particle
concentration, Lp(a), renal function and inflammation
biomarkers, among others (17, 18 ).
The analytical validity of these markers and their
incremental value beyond LDLC is strongly debated
among laboratory professionals and clinicians. Other ex-
pert panels have undertaken efforts to investigate emerg-
ing biomarkers that are not related to lipid metabolism
(17, 18 ). The current multidisciplinary consensus panel
has been established by the European Federation of Clin-
ical Chemistry and Laboratory Medicine (EFLM) and
the European Atherosclerosis Society (EAS) with the aim
of critically addressing the key issues of the lipoprotein
and apolipoprotein markers identified above, as well as
reaching a consensus on contemporary laboratory testing
for CVD risk assessment and management of lipid ther-
apies. This article embodies the consensus-based recom-
mendations (CBRs) of this expert panel, summarized in
Table 2.
Which Atherogenic Lipoproteins Should Be
Measured?
Are we using the appropriate biomarker? Standard LDLC
assays measure the cholesterol content of LDL particles,
expressed as milligrams per deciliter (or mmol/L) of cho-
lesterol. LDLC concentration can be measured directly
(dLDLC) with several different assays, but is still often
calculated (cLDLC) from a standard lipid profile that
includes measurements of total cholesterol (TC), HDLC,
and triglycerides (TG). Fasting blood samples have been
the standard for determining lipids because measuring
them in the fasting state reduces variability of TG con-
centrations, thus allowing for a more accurate cLDLC
estimation with the Friedewald equation. When the ini-
tial clinical decision cutpoints were developed, they were
mainly derived from population studies using fasting
samples. Thus, recommendations about use of fasting
samples in patient care were made to ensure that results
and cutpoints are comparable with those used in these
studies. However, fasting is no longer routinely required
for the determination of a lipid profile (19, 20 ). Nonfast-
ing lipid profiles are now endorsed by several societies’
Table 2. Key CBR to improve the clinical use of atherogenic lipoprotein assays.
CBR1 Comprehensive assay(s) of atherogenic lipoproteins should assess the risk conferred by LDL particles,
remnant particles, and Lp(a).
CBR2 Laboratories and clinical trial centers should report lipid proﬁles with declaration of the assay
method/manufacturer used.
CBR3 Follow-up of lipid proﬁles of a patient, from baseline at diagnosis to on-treatment measurements,
should be ideally performed with the same assay method (and preferably the same laboratory and
instrument).
CBR4 Values near the treatment decision cutpoints should be conﬁrmed by ≥2 repeated measurements by
the same method and then averaged.
CBR5 Laboratories should automatically calculate and report non-HDLC on all lipid proﬁles.
CBR6 Non-HDLC adds Remnant-C to LDLC and can be calculated in the fasting and nonfasting state,
independent of TG variability.
CBR7 ApoB assay can estimate LDLP (95% of apoB) plus Remnant-P and Lp(a) particle numbers in the
fasting and nonfasting state.
CBR8 LDLC is the primary target of lipid-lowering therapy. When LDLC goal is achieved, then non-HDLC or
apoB should be preferred as secondary treatment targets in patients with TG >175 mg/dL (>2
mmol/L), obesity, metabolic syndrome, or type 2 diabetes.
CBR9 When LDLC is unavailable because of an invalid Friedewald equation (TG >400 mg/dL; 4.5 mmol/L),
follow-up calculation of non-HDLC should be used at higher TG concentrations rather than
additional direct LDLC measurement.
CBR10 Lp(a)-corrected LDLC should be assessed at least once in patients with suspected or known high
Lp(a), or if the patient shows a poor response to LDL-lowering therapy.
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guidelines, including those in Europe, Canada, and the
US (1, 3, 4 ).
Findings from population studies show that despite
minor postprandial increases in TG and remnant choles-
terol, quantitative changes in other lipids, lipoproteins,
and apolipoproteins appear to be negligible in response to
the habitual meal intake for most individuals (19–21).
Nonfasting lipid profiles are, as we have earlier recom-
mended (19 ), likely to bemore relevant to the estimation
of an individual’s CVD risk than fasting lipids (22 ), in-
cluding TG (23 ), because in real life we spend most of
our time in a postprandial state (20 ). However, even
whenmeasured in the nonfasting state, LDLC alone does
not account for all the risk conferred by atherogenic li-
poproteins described hereafter. Please note that although
we use the term atherogenic lipoproteins when we refer
jointly to LDL, remnant lipoproteins, and Lp(a), this
does not imply that the mechanism by which these lipo-
proteins cause CVD is identical.
REMNANT PARTICLES
Postprandial accumulation of TG-rich remnant parti-
cles in blood is an important factor in atherogenesis
(8, 9, 24 ). These lipoproteins contain a higher load of
cholesterol that is not considered in typical fasting TG-
or LDLC-related risk estimations. TG-rich chylomicrons
secreted from the intestine, as well as VLDL secreted
primarily from the liver, are remodeled in the circulation
primarily through the actions of lipoprotein lipase (LPL),
hepatic lipase, and cholesteryl ester transfer protein
(CETP). The hydrolysis of TG by LPL and acquisition of
cholesteryl esters from HDL by CETP generate smaller
remnant particles that are depleted of part of their TG
content. Consequently, TG-rich lipoproteins also en-
compass cholesterol-enriched remnants—with the rare
exception in individuals with familial chylomicronemia
owing to complete deficiency of LPL or 1 of its key co-
factors such as apoC-II and apoA-V (estimated inci-
dence, 1/million) (13 ). There is persuasive experimental
evidence that these remnant particles may enter the arte-
rial intima and contribute to atherosclerosis, whereas nas-
cent chylomicrons and very large VLDL particles are too
large initially to cross the endothelial layer (8, 24 ). Un-
like LDL particles, which need to be modified (e.g., by
oxidation) to generate ligands of the macrophage scaven-
ger receptor, TG-rich remnants can be taken up directly
(without modification) by monocyte-derived macro-
phages, leading to the formation of foam cells, a key step
in development of atherosclerotic plaques. Another
mechanism by which these particles may predispose an
individual to CVD involves the concept that LPL activity
catalyzes the release of free fatty acids from TG-rich rem-
nant particles, resulting in local endothelial injury and
arterial inflammation (24 ). Mendelian randomization
studies suggest that life-long high plasma concentrations
of TG-rich lipoproteins or their remnants are causally
associated with increased risk of coronary heart disease
(CHD) (25–28) and all-cause mortality (29 ).
Accurate isolation and quantification of remnants
has previously been problematic, as remnants are difficult
to differentiate from their larger and more TG-rich pre-
cursors; furthermore, their plasma concentration is typi-
cally much lower compared with other lipoproteins.
There are several early assays that claim to specifically
measure cholesterol in remnants, but they show poor
agreement (30 ). Some have been validated in cohort
studies and have revealed significant associations of rem-
nant cholesterol with cardiovascular events (31, 32 ).
Larger data sets have been obtained by the calcula-
tion of “remnant cholesterol” (Remnant-C  TC 
HDLC LDLC) because Remnant-C corresponds to all
cholesterol not found in LDL and HDL, i.e., in all TG-
rich lipoproteins (Fig. 1). In the fasting state, this consti-
tutes cholesterol in VLDL and intermediate-density lipo-
proteins (IDLs), whereas in the nonfasting state, a
relatively small amount of cholesterol can also be found
in chylomicron remnants. Because both newly secreted
chylomicrons and VLDL are acted on rapidly by LPL,
any circulating chylomicrons and VLDL have undergone
some partial lipolysis and hence can be considered rem-
nants (24 ). If Friedewald-cLDLC is used in the calcu-
lation, then Remnant-C simply equals TG/2.2 (in
mmol/L) or TG/5 (in mg/dL) and does not provide any
clinical information beyond TG concentrations; how-
ever, this is not the case if dLDLC is used in the calcula-
tion. Importantly, a homogeneous direct assay to mea-
sure Remnant-C in all TG-rich lipoproteins combined
has become available to be used with standard hospital
autoanalyzers, and direct Remnant-C is highly correlated
with calculated Remnant-C, although not identical (33 ).
Remnant-C also contributes to non-HDLC, which is
calculated as the difference between TC and HDLC (19).
This term is independent of the Friedewald term and, there-
fore, not confounded as much with TG concentrations as
calculatedRemnant-C; thus, it represents an additional clin-
ically valuable marker (19). Remnant-C, measured or cal-
culated, differs from non-HDLC in that non-HDLC con-
tains Remnant-C plus LDLC (Fig. 1). Some individuals
with high Remnant-C have low LDLC, and if interpreting
non-HDLC instead of Remnant-C, then high Remnant-C
will be masked in these individuals.
LDL PARTICLES
All LDL particles are highly atherogenic, but their con-
centration is not always reflected by LDLC measure-
ments, particularly in hypertriglyceridemic patients with
diabetes or related conditions such as visceral obesity and
insulin resistance, which are critical components of the
metabolic syndrome (13 ). LDLC concentration does not
automatically equal LDLP because the cholesterol/TG
Atherogenic Lipoprotein Tests: Current and Future Challenges Special Report
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ratio in the particles can vary widely between individuals,
reflecting differences in LDL subfraction profile (34 ).
Small LDL particles contain less (LDL) cholesterol than
large ones. Although LDLC is typically not increased in
patients with type 2 diabetes, such patients tend to have
smaller average LDL particle size and will have concom-
itantly more LDL particles than a patient with the same
LDLC concentration who has larger average LDL size
(34 ). These small LDL particles, typically predominant
in those with mild to moderate hypertriglyceridemia, are
the products of intravascular remodeling of larger TG-
rich VLDL particles by 2 processes: first, the progressive
hydrolysis of TG-rich VLDL by LPL; second, the in-
creased exchange and transfer of TG and cholesteryl ester
mediated by CETP to produce TG-enriched LDL parti-
cles (13 ). TGs are then hydrolyzed by hepatic lipase,
resulting in smaller and denser LDL particles with less
cholesteryl ester per particle. These compact, lipid-
depleted LDL particles are less efficiently cleared via he-
patic LDL receptors (35 ), leading to higher LDLP in
patients with increased TG than would be predicted
based on LDLC measurement. Concomitantly, TG-
enriched HDL resulting from the action of CETP is also
modified by hepatic lipase, producing smaller HDL and
contributing to lower concentrations of HDLC, as typi-
cally manifested in the atherogenic dyslipidemic triad
involving hypertriglyceridemia, increased small dense
LDLP, and low HDLC (35 ).
Measurement of apoB, the major protein compo-
nent of LDL, can also be used to assess the number of
LDL particles (36 ); however, an apoB measurement also
includes Lp(a), IDL, VLDL, and chylomicron remnants
(Fig. 1). ApoBmeasurement is not, however, usually part
of the standard lipid profile. Monogenic disorders that
impair the removal of LDL particles from the circulation,
such as familial hypercholesterolemia, can be easily rec-
ognized from the standard lipid profile without apoB. In
contrast, polygenic hypertriglyceridemia or combined
hyperlipidemia can be more adequately characterized
based on TG and apoB (37 ). Although not widely avail-
able, LDLP measured by nuclear magnetic resonance
(NMR) spectroscopy provides an alternative measure of
the number of LDL particles and has been shown to be at
least equivalent to apoB and non-HDLC in predicting
cardiovascular risk (38 ).
Lp(a) PARTICLES
Lp(a) is an LDL-like particle with 1 molecule of apoB to
which an additional apolipoprotein, apo(a), is covalently
attached. This apolipoprotein shows considerable size
polymorphism originating from a variable number of
kringle IV type 2 (KIV-2) repeats of apo(a), as encoded
Fig. 1. Lipoproteins separated according to density and size and their representative laboratory markers measured in a blood
sample.
Standard lipid proﬁles consist of measurements of TC, TG, HDLC, and LDLC; however, a standard lipid proﬁle could also report calculated
Remnant-C and calculated non-HDLC. Remnant-C, calculated as TC − HDLC − LDLC, is all cholesterol not found in LDL and HDL, i.e., in all
TG-rich lipoproteins: VLDL, IDL, and, in the nonfasting state, chylomicron remnants. Non-HDLC, calculated as TC − HDLC, represents a
comprehensivemeasure of all cholesterol found in atherogenic lipoproteins: LDLC, Remnant-C, and Lp(a) cholesterol. ApoB and apoA1 can be
used as alternatives to non-HDLC and HDLC. The cholesterol content of Lp(a), corresponding to approximately 30% of Lp(a) total mass, is
included in TC, non-HDLC, and LDLC measurements and its apoB content in the apoB measurement.
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by tandem repeats of a genomic sequence in the LPA21
gene (10, 39 ). This size polymorphism is the most im-
portant determinant of the hepatic production rate of
Lp(a), and results in marked interindividual variation of
plasma Lp(a) concentrations by1000-fold. Individuals
expressing a low number of KIV-2 repeats [small apo(a)
phenotypes] show, on average, markedly higher Lp(a)
concentrations than those with a high number of KIV-2
repeats [large apo(a) phenotypes], who, on average, have
low Lp(a) concentrations. An increased Lp(a) concentra-
tion is a strong genetic risk factor for CVD and calcific
aortic valve stenosis independent of LDLC in the general
population (10, 39, 40 ). One of the major differences
between these 2 particles is that LDLs are effectively low-
ered by statins, whereas Lp(a) is typically resistant to this
treatment. Although PCSK9 inhibitors and other novel
agents reduce both LDLC and Lp(a) (12 ), it is unknown
whether Lp(a) lowering per se contributes to the clinical
benefit of these novel agents.
Lp(a) should be measured in all patients screened for
high risk of CVD or aortic stenosis, in cases of premature
CVD, and in those with a positive family history of CVD
or high Lp(a) (10 ). It is often a likely reason of otherwise
unexplained CVD cases. However, Lp(a) measurement
should not be included in repeated lipid profile measure-
ments within the same patient [as Lp(a) concentrations
exhibit little variation over a lifetime], unless treatment is
known to influence Lp(a) concentrations. Importantly,
the cholesterol content of Lp(a) is included in calculated
and measured LDLC and, consequently, also TC and
non-HDLC values (19 ).
Consensus-based recommendation. Comprehensive testing
of atherogenic lipoproteins should use a biomarker, or a
panel of multiple markers, that can be measured in either
the fasting or nonfasting state and assesses the risk asso-
ciated not only with LDL particles but also remnant par-
ticles and Lp(a) (CBR1). The use of atherogenic lipopro-
tein testing in different clinical settings such as CVD risk
estimation, dyslipidemia diagnosis, risk management,
and treatment has been emphasized in other guidelines
(1 ) (Table 3).
Are LDLC Measurements or Calculations
Reliable?
OPERATIONAL DEFINITION OF LDL
Most manufacturers of lipid assay kits certify and stan-
dardize their assays by comparison with a Cholesterol
ReferenceMethod LaboratoryNetwork (CRMLN) labora-
tory. The CRMLN standardization process ensures that
the calibrators and reagents sold by manufacturers pro-
duce test results that are traceable to the CDC refer-
ence methods, i.e., -quantification for LDLC and
ultracentrifugation/heparin-Mn2 precipitation for
HDLC (41 ).
-Quantification requires ultracentrifugation of se-
rum or plasma at a density of 1.006 g/mL to separate the
supernatant, which contains VLDL and chylomicrons,
from the infranatant, which contains LDL, HDL, and21 Human Gene: LPA, lipoprotein(a).
Table 3. CBRs for the clinical indication for atherogenic lipid and lipoprotein quantiﬁcation.
CVD risk
estimation
Dyslipidemia
characterization
Treatment
choice
Treatment
target Desirable value
TC Yesa Optionalb Optionalb Optionalb <190 mg/dL (5.0 mmol/L)
LDLC Yes Yes Yes Yes Low to moderate risk <115 mg/dL (3.0 mmol/L)
High risk <100 mg/dL (2.5 mmol/L)
Very high risk <70 mg/dL (1.8 mmol/L)
TG Yes Yes Yes No Fasting <150 mg/dL (1.7 mmol/L)
Nonfasting <175 mg/dL (2.0 mmol/L)
Non-HDLC Yes No No Yesc Moderate risk <145 mg/dL (3.8 mmol/L)
High risk <130 mg/dL (3.3 mmol/L)
Very high risk <100 mg/dL (2.5 mmol/L)
ApoBd Optionalc Yesc No Optionalc High risk <100 mg/dL (1.0 g/L)
Very high risk <80 mg/dL (0.8 g/L)
a In combination with HDLC.
b To be considered when LDLC is not available.
c In patients with mild to moderate hypertriglyceridemia (2–10 mmol/L; 175–880 mg/dL).
d Or LDLP if available.
To convert mmol/L to mg/dL, multiply by 38.6 for cholesterol and 88.5 for TG.
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Lp(a). Cholesterol is measured in the infranatant to provide
the sum of LDL, HDL, and Lp(a) cholesterol, and then
LDL particles, including Lp(a), are precipitated from the
infranatant, and HDLC is measured in the remaining su-
pernatant. LDLC is then calculated as infranatant choles-
terol minus supernatant (HDL) cholesterol, both mea-
sured with the Abell–Kendall cholesterol reference method
(41). However, it is not widely recognized that this LDLC
also contains the cholesterol from Lp(a), which can be sub-
stantial in the case of highLp(a) concentrations50mg/dL
(10).
An important prerequisite for reference standardiza-
tion of the LDLC and HDLC assays is an unambiguous
definition of the lipoproteins intended to be measured.
With -quantification, the lipoprotein fraction in the
density range of 1.006 to 1.063 g/mL is defined as LDL,
and the fraction in the density range of 1.063 to 1.21
g/mL is defined as HDL (41 ). Yet, these operational
definitions allow variable degrees of cross-reactivity of
cholesterol from IDL with a density of 1.006 to 1.019
g/mL and Lp(a) with a density of 1.04 to 1.13 g/mL in
the LDLC fraction using -quantification. Direct assays
that attempt to specifically measure cholesterol in LDL
may, therefore, show discordant results compared with
the reference method (15 ).
DIRECT LDLC AND HDLC ASSAYS
In the previous century, the earliest measurements of li-
poproteins involved ultracentrifugation and (most pop-
ular) precipitation techniques for isolation of LDL and
HDL (42 ). In the late 1990s, “homogeneous” or “direct”
LDLC and direct HDLC (dHDLC)methods were intro-
duced in clinical laboratories and have since largely re-
placed the older assays, particularly for HDLC (15, 42 ).
The homogeneousmethods are commercially available as
ready-to-use reagents, enabling fully automated dLDLC
and dHDLC measurements from the primary blood
sample tube, without any need for ultracentrifugation or
precipitation to separate HDL and LDL particles. There
are various dLDLC and dHDLC assays available based
on different principles from different manufacturers to
selectively isolate and measure cholesterol in these lipo-
proteins. Despite the ease of use and cost savings, mostly
because of automation, substantial nonselectivity errors
have been reported for many of the direct assays (15, 42 ).
According to National Cholesterol Education Pro-
gram (NCEP) criteria, the total error of LDLC and
HDLC measurements should be within 12% and 13%,
respectively, of the true value (41, 43 ). The total error
term combines 2 analytical components: imprecision and
bias. Imprecision refers to the reproducibility of a
method, the “random error” often reported as a CV. Bias,
or inaccuracy, refers to a systematic difference in results
between a method and the “true” or reference value: It
should be4% for LDLC and5% for HDLC to allow
the methods to meet the total error goals (41, 43 ). The
discordance between measurements and “true” values,
assigned by the reference method, is caused by both bias
(which in theory can be eliminated) and imprecision
(which can only be minimized but not avoided) in the
tests. The directmethods are well standardized using nor-
mal patient samples and demonstrate improved precision
because of the elimination of sample pretreatment steps,
but their bias is a major point of concern in case of aber-
rant sample matrices, e.g., owing to dyslipidemia. Un-
solvable errors—regardless of the method used (ultracen-
trifugation, precipitation, or homogeneous assays)—
relate to the ambiguity in the operational definition of
“LDL” and “HDL” fractions and the heterogeneity of
LDL and HDL particles. Both LDL and HDL fractions
comprise different subclasses of particles that vary in size,
density, shape, and lipid and apolipoprotein composi-
tion, without any definitive chemical structure, making
development of specific assays difficult (15, 42 ). Direct
assays based on different principles may select different
subclasses of LDL or HDL that may or may not be
equally quantified, depending on the assay procedure and
reagents. The reaction specificities of dLDLC assays vary
regarding reactivity to small dense LDL subfractions and
nonspecific reactivity to VLDL subfractions (15 ). Con-
sequently, nonspecificity bias is caused by the inaccuracy
of the tests in selectively quantifying what is intended to
be measured; this bias is inevitable and varies per sample
(15, 42, 44 ).
Most discrepancies—with marked deviations from
the CDC reference methods—are observed in samples
from patients with hypertriglyceridemia 2 mmol/L
(175 mg/dL), mixed dyslipidemia, or other conditions
involving altered lipoprotein composition and remodel-
ing, such as diabetes and chronic kidney disease (44–
46). In a comprehensive study of direct methods using
fresh samples from individuals with and without CVD
and/or various dyslipidemias, Miller et al. showed that
only 5 of 8 dLDLC methods and only 6 of 8 dHDLC
methods met the NCEP total error goal with samples
from nondyslipidemic individuals, and all methods failed
to meet NCEP performance criteria with those from dys-
lipidemic individuals (44 ). The total error of dHDLC
and dLDLC measurements ranged approximately 13%
in normolipidemic samples but from20% to36% for
dHDLC and26% to32% for dLDLC in dyslipide-
mic samples (44 ). Most discordant results were observed
at lower concentration ranges of HDLC (40 mg/dL)
and LDLC (70 mg/dL) (44 ), which are now more
clinically relevant given the highly efficacious LDL-
lowering therapies presently available.
Test results differ substantially between the various
direct methods from different manufacturers, particu-
larly in hypertriglyceridemic (2 mmol/L; 175 mg/
dL) samples. For all dHDLC and dLDLC methods, a
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high proportion (10%; for somemethods, 30%–45%)
of test results fall outside the NCEP total error goals in
dyslipidemic samples (44 ). We cannot recommend a
specific manufacturer method, as no consistent pattern
has been documented for the frequency of analytical er-
rors with each method in normolipidemic or dyslipide-
mic samples. This is also evident from large-scale
accuracy-based quality surveys organized across different
laboratories (47, 48 ). In a survey of 190 US laboratories,
all dLDLC methods failed the bias criterion of4% on
a fresh frozen pooled serum with a TG concentration of
2.2 mmol/L (193 mg/dL) (47 ). An external quality as-
sessment (EQA) study of 200 clinical laboratories in the
Netherlands, representing common dLDLC and dH-
DLCmethods used inmost countries, revealed unaccept-
able bias (up to 20%) with most manufacturers’ methods
in fresh and frozen serum pools, with TG concentrations
of 7 mmol/L (620 mg/dL) (48 ). Reported dLDLC data
showed values for mean bias of 16% with Abbott Di-
agnostics,14%with Beckman Coulter, and7%with
Roche Diagnostics methods as compared with the
CRMLN reference laboratory measurement (48 ). Mean
dHDLC biases were also method-dependent [3% (Ab-
bott), 7% (Beckman Coulter), 19% (Roche), and
22% (Siemens)] and contributed to between-laboratory
variability of cLDLC and non-HDLC calculations (48).
These errors resulted in misclassifications with respect to
CVD risk assessment, depending on the laboratory where
LDLC or HDLC was measured (48).
The biases noted in dLDLC and dHDLC assays
when analyzing dyslipidemic samples with atypical lipo-
proteins suggest that nonspecific cross-reaction takes
place, with high variability between the different chemi-
cal procedures used to isolate the lipoproteins intended to
be measured. This shortcoming is not revealed in current
CDC certification programs.
cLDLC
In most laboratories, LDLC is calculated by the Friede-
wald formula, cLDLC  TC  HDLC  VLDL cho-
lesterol (VLDLC), wherein VLDLC is estimated as TG/
2.2 in mmol/L or TG/5 in mg/dL (49 ).
Like dLDLC measurements, cLDLC calculation is
not without flaws. The Friedewald formula also includes
cholesterol in IDL and Lp(a) and assumes a constant
VLDL TG/cholesterol ratio, lack of chylomicrons, and
lack of excessive remnant lipoproteins. Nonfasting sam-
ples do not necessarily meet these assumptions, as chylo-
microns may be present and are more TG-rich than
VLDLparticles (42 ). Because the TG/cholesterol ratio in
TG-rich VLDL and chylomicrons progressively increases
as hypertriglyceridemia and (postprandial) chylomi-
cronemia become more severe, the equation overesti-
mates VLDLC and, therefore, underestimates LDLC at
high TG concentrations (42 ). In a study of type 2 diabe-
tes patients, postprandial decrease in LDLC was 12%
with nonfasting cLDLC vs 5% on beta-quantification
at 5 h postprandially (50 ). Hence, cLDLC exaggerates
the (usually minor) postprandial decrease in LDLC,
which is clinically insignificant in most individuals (19 ).
The equation is increasingly inaccurate at TG concentra-
tions from 200 to 400 mg/dL (2.3–4.5 mmol/L) and is
regarded as invalid when TGs are 400 mg/dL (4.5
mmol/L) or in rare cases of type III dyslipoproteinemia in
which cholesterol-rich -VLDL remnants are present
and VLDLC will be underestimated (therefore, LDLC
will be overestimated) (13, 42 ). Several alternative
cLDLC equations and adjustable factors for the TG/
VLDLC ratio have been proposed (51–54), but it re-
mains to be determined as to whether improvements over
the Friedewald equation improve risk prediction or are
substantive enough to justify their implementation in
clinical practice (55 ). The fact that cLDLC depends on 3
laboratory measures, i.e., TG, TC, and dHDLC, means
that 3 CVs are involved, which increases the potential for
measurement error (Table 4).
Both imprecision and bias of cLDLC increase at lower
LDLC concentrations, an aspect that is more relevant be-
cause highly effective LDL-lowering therapies, including
combination therapies (e.g., statins with ezetimibe or statins
Table 4. Analytical and biological sources of error in
variables included in the Friedewald-cLDLC equation.
TC
(Pre-)analytical and intraindividual (biological)
variations of TC
Lp(a) cholesterol in patients with increased Lp(a) is
not subtracted from TC
HDLC
(Pre-)analytical and intraindividual (biological)
variations of HDLC
Inaccurate dHDLC measurement (nonspeciﬁcity bias)
in dyslipidemic samples
VLDLC
TG/cholesterol ratio increases with increasing
hypertriglyceridemia
Invalid use of ﬁxed TG/cholesterol ratio in type III
dyslipoproteinemia and chylomicronemia
Intraindividual (biological) variations of TG
Postprandial variations of TG, when using nonfasting
samples
Increased free glycerol concentration in nonglycerol
blanked TG assaysa
a The free or endogenous glycerol concentration in a sample can usually be ignored
[1 mg/dL, equivalent to approximately 10 mg/dL (0.11 mmol/L) of TG]. Increased
baseline glycerol concentrations are found in patients with diabetes and chronic
kidney disease, and will add to underestimation of cLDLC using nonglycerol
blanked TG assay.
Atherogenic Lipoprotein Tests: Current and Future Challenges Special Report
Clinical Chemistry 64:7 (2018) 1013
with PCSK9 inhibitors), are now available (11, 12). The
original Friedewald equation in1972was not designed to be
used in patients receiving such treatments. In a correlation
analysis of pooled data from 14 trials of alirocumab-treated
patients in the ODYSSEY program, only minor differences
were observed between LDLC values derived by Friedewald
calculation and -quantification (56). In patients with
LDLC in the range of 15 to 25 mg/dL (0.4 to 0.6
mmol/L) as measured by -quantification, there was a me-
dian difference of 3.5 mg/dL (0.1 mmol/L) compared with
cLDLC; in those with measured LDLC 15 mg/dL (0.4
mmol/L), there was a median 3-mg/dL (0.1-mmol/L) dif-
ference (56). These small differences are likely to have little
clinical impact. Another report showed that underestima-
tion of LDLC by the Friedewald equation compared with
ultracentrifugation (-quantification), especially an LDLC
70 mg/dL (1.8 mmol/L) with a median difference of
4 mg/dL (0.1 mmol/L), resulted in treatment group
misclassification of 29% of patients with respect to the
guideline-recommended cutpoint of 70 mg/dL (1.8
mmol/L) (55 ). These studies reported pooled data from
predominantly (75%) normotriglyceridemic study
populations (55, 56 ). In a subanalysis of 33 106 hyper-
triglyceridemic patients with TGs of 200 to 399 mg/dL
(2.3–4.5 mmol/L) from a large study sample (n 
191333) with cLDLC ranging from 2 to 70 mg/dL
(0.05 to 1.8 mmol/L), median cLDLC bias was 18
mg/dL (0.5 mmol/L) (5th to 95th percentile, 7 to
36 mg/dL; 0.2 to 0.9 mmol/L) compared with
LDLC measured by vertical spin density gradient ultra-
centrifugation (57 ).Median biases were larger at the low-
est concentration ranges:26 mg/dL (0.7 mmol/L) at
cLDLC of 15 to25 mg/dL (0.4 to0.6 mmol/L), and
33 mg/dL (0.9 mmol/L) at cLDLC of 15 mg/dL
(0.4 mmol/L) (58 ). The same investigators found that
cLDLC was frequently classified as 70 mg/dL (1.8
mmol/L) despite true LDLC concentrations 70 mg/dL;
indeed, 39%of patients weremisclassified whenTG con-
centrations were 150 to 199 mg/dL (1.7–2.3 mmol/L),
and 59%were done so when concentrations ranged from
200 to 399 mg/dL (2.3–4.5 mmol/L) (57 ). These pa-
tients may be excluded from treatment because of under-
estimated LDLC (57, 58 ). It should be noted that the
target (i.e., 70 mg/dL; 1.8 mmol/L) is based on popula-
tion studies using cLDLC and not ultracentrifugation;
thus, it could be argued that ultracentrifugation (-
quantification) is the method that misclassifies risk.
These observations reflect the inaccuracy of the Frie-
dewald equation over the full range of LDLC values seen
with novel therapies. In persons with very low LDLC and
concurrently high TG, VLDLC estimation (TG/5 in
mg/dL or TG/2.2 in mmol/L) constitutes a relatively
larger portion of the equation. In this situation, the error
of overestimated VLDLC with increasing TG-rich
VLDL has a significant impact on the total error of esti-
mated cLDLC.
EFFECT OF Lp(a) CHOLESTEROL ON LDLC
Friedewald-estimated cLDLC and most dLDLC meth-
ods include the cholesterol that is present in Lp(a) parti-
cles (15, 59 ). Considering that an Lp(a) particle is com-
posed of about 30% to 45% cholesterol by weight, a
substantial overestimation of TC, non-HDLC, and
LDLC concentration occurs in individuals with high and
very high Lp(a) concentrations (59 ); for example, if a
person has an Lp(a) concentration of 100 mg/dL,
cLDLC and dLDLC will be overestimated by 30 to 45
mg/dL (0.8–1.2 mmol/L). These circumstances might
explain some cases of nonresponse or low response to
statin treatment. Statins are known to have a pronounced
effect on LDLC but do not lower Lp(a) concentrations
(60 ).
If a patient receives a statin with the aim to reduce
LDLC to a target of 70 mg/dL, and if that patient
already has a cLDLC value of 100 mg/dL and an Lp(a)
concentration of 100 mg/dL, the Lp(a)-corrected LDLC
is only approximately 55 to 70 mg/dL [i.e., 100 mg/dL
cLDLC minus 30%–45% of measured Lp(a)]. In the
new era of potent LDLC-lowering therapies, the
achieved true LDLC concentrations [after correction for
Lp(a) cholesterol] can be as low as 10 mg/dL (0.3
mmol/L) (61 ). This scenario is particularly likely in
African-Americans, who often have 2- to 3-fold higher
Lp(a) concentrations than whites, or in patients with ne-
phrotic syndrome or in those undergoing peritoneal di-
alysis in whom Lp(a) concentrations can reach up to
300 mg/dL, which corresponds to an Lp(a)-corrected
LDLC that is 135 mg/dL (3.5 mmol/L) lower than the
uncorrected LDLC value (62 ). For example, patients
with nephrotic syndrome had, on average, 27-mg/dL
higher LDLC concentrations if not corrected for choles-
terol derived fromLp(a) (compared with only 9mg/dL in
controls) (62 ).
Lp(a)-corrected LDLC can be estimated with the
Dahlen modification of the Friedewald formula, which
assumes that 30% of Lp(a) weight consists of cholesterol:
cLDLC  TC  HDLC  TG/5  [Lp(a) 	 0.30] in
mg/dL (63 ). We recommend that Lp(a)-corrected
LDLC be applied at least once in patients with sus-
pected high Lp(a), or in a patient who does not re-
spond sufficiently to statin therapy, to identify or ex-
clude potential interference by high or very high Lp(a)
in making treatment decisions (CBR10). If a high
Lp(a) concentration is the cause for an apparently dis-
appointing LDLC-lowering response with a statin,
then it might not be useful to increase the dosage of
statin under such conditions (60 ).
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DISCORDANT cLDLC VS dLDLC
Measured and calculated LDLC correlate well using both
fasting and nonfasting lipid profiles in general population
statistics (19), but often cLDLC may not agree with
dLDLC in an individual subject (15). Friedewald-cLDLC
with a constant TG/cholesterol ratio cannot adjust for the
postprandial increase in TG (42). -Quantification re-
moves TG-rich lipoproteins by ultracentrifugation before
measurement, and most dLDLC assays attempt to selec-
tively measure cholesterol in LDL particles by either block-
ing or solubilizing non-LDL particles (15). Thus, techni-
cally, -quantification and dLDLC are less sensitive to
TG-rich lipoproteins and should not be influenced by a
nonfasting state, but thedirect assays have varying specificity
limitations when abnormal lipoproteins and increased TG
are present (44–46).
Among 1508 men (including 173 CHD events dur-
ing follow-up) and 1680 women (including 74 incident
CHD events), the Framingham Study found good agree-
ment of cLDLC with dLDLC (Kyowa Medex assay)
(64 ). Discrepancies of 10% were assessed in 7.7% of
LDLC determinations, but at higher TG concentrations
and in patients with diabetes, CHD, or on cholesterol-
lowering medications, there was a greater bias between
the 2 methods (64 ). This study, as in the Women’s
Health Study below, did not compare either the cLDLC
or the dLDLC method with a gold standard such as ul-
tracentrifugation. The Women’s Health Study (n 
27331) also observed good correlations between cLDLC
and dLDLC (Roche Diagnostics assay) in fasting and
nonfasting samples (65 ). However, the average dLDLC
concentration was 5 to 10 mg/dL (0.1–0.3 mmol/L)
lower than cLDLC. Associations of fasting cLDLC and
dLDLC concentrations with CHD events showed simi-
lar hazard ratios (HRs) of 1.22 (95%CI, 1.14–1.30) and
1.23 (95% CI, 1.15–1.32) per 1-SD increase (35 and 34
mg/dL; 0.9 and 0.9 mmol/L), respectively. However, the
lower dLDLC resulted in classification of about 20%
of individuals with discrepant risk as compared with
cLDLC (65 ).
Even in normotriglyceridemic samples, dLDLC
methods do not offer advantage over cLDLC in classify-
ing patients into NCEP risk categories when compared
with the reference method (66 ). In a study of 145 fasting
individuals with TG200 mg/dL (2.3 mmol/L), 7 of 8
commercially available dLDLC methods failed to show
improved CVD risk score classification over the corre-
sponding cLDLC estimated using the dHDLC method
from each manufacturer in the calculation (66 ). The
overall misclassification rate for the CVD risk score
ranged from 5% to 17% for cLDLC methods and from
8% to 26% for dLDLC methods when compared with
-quantification, and most normotriglyceridemic indi-
viduals were classified into a lower risk category by the
dLDLC methods (3%–26%) (66 ).
These observations suggest no substantial advantage
for using dLDLC compared with cLDLC in normotrig-
lyceridemic and hypertriglyceridemic blood samples up
to TG concentrations of 400 mg/dL (4.5 mmol/L).
dLDLC measurement is clearly more expensive than the
“free of charge” cLDLC. Furthermore, most clinical trials
demonstrating the evidence base for clinical benefit of
LDLC lowering with statin therapy have used the Frie-
dewald equation.
LDLC TEST ERRORS: ARE THEY CLINICALLY RELEVANT?
Clinical or epidemiological studies can validate whether
analytical errors in LDLC testing are relevant in clinical
decision-making and whether they influence outcomes.
The ranges of uncertainty across different LDLC meth-
ods are not negligible (Table 5). Difficulties in treatment
options may arise when LDLC test results are close to
guideline-driven critical values that determine the decision
of therapeutic intervention (Fig. 2). Misclassification—
and, thus, inappropriate treatment—may occur if a true
LDLC concentration is above the optimal target value
but the reported LDLC value is in a desirable range, or if
a true LDLC concentration is in a desirable range but the
reported LDLC value is above target, e.g., 70 mg/dL (1.8
mmol/L), in a patient with a very high-risk score (1 ). The
former underdiagnosis bears the risk of insufficient treat-
ment and adverse clinical outcome; the latter overdiag-
nosis will increase costs by leading to unnecessary prescrip-
tions of statins in general and specifically combination
treatments.
Depending on the methods used, different treat-
ment decisions may be taken, or confusion may arise if
the patient’s samples for monitoring are sent to different
laboratories using differentmethods or when a laboratory
changes the method. Not uncommonly, changes in a
patient’s LDLC test result over time are within the range
of uncertainty of laboratory method variation and may
not be because of therapeutic intervention. Between-
method and between-laboratory differences in on-
treatment LDLC may even mimic (or mask) a nutraceu-
tical or pharmaceutical effect, e.g. ezetimibe, when values
differ 15% over time when measured by different
methods during follow-up (67 ). Based on the Choles-
terol Treatment Trialists’ metaanalysis (6 ), measurement
biases of up to0.5 mmol/L (20mg/dL) can be falsely
interpreted as a 10% CVD risk reduction (Fig. 3). For
example, in the REVEAL study, the mean LDLC reduc-
tion in the anacetrapib-treated group compared with the
placebo groupwas26mg/dL (0.68mmol/L;41%)
as measured with a direct assay (Beckman Coulter) but
only11 mg/dL (0.28 mmol/L;17%) as measured
on -quantification in the same samples (68 ). These is-
sues are, however, less relevant for the monitoring of the
patient by the same laboratory and method over time. In
this situation, the bias remains constant over time and
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only the imprecision (random error) is relevant, which
may not be important given that clinicians are not aiming
to achieve the LDLC targets exactly but often concentra-
tions below it. In the present era, the extent of LDLC
reduction is more important than achieving specific targets,
and recent guidelines suggest that achievement of a50%
reduction in high- and very high-risk patients is paramount,
irrespective of baseline LDLC concentration (2).
The risk that errors in LDLC measurement affect
the clinical decision is further attenuated by the NCEP
recommendation that decisions to initiate a treatment, or
adjusting or shifting to another treatment, should not be
taken on 1 LDLCmeasurement but rather after multiple
repeated measurements (at least 2 times) to allow for
intraindividual (biological) variation (43 ).
Consensus-based recommendation. Analytical performances
of dLDLC and cLDLC are acceptable in blood samples
with normal TG. That said, variable nonspecificity errors
may confound measurements in samples with hypertri-
glyceridemia175 mg/dL (2 mmol/L), which is seen in
approximately 25% of individuals in the general popula-
tion (24 ), or in samples with low LDLC70mg/dL (1.8
mmol/L); however, these errors may still be less than the
between-method, between-laboratory, biological, and,
thus, total error. We recommend that laboratories and
clinical trial centers report lipid levels together with the
test method used, and in a similar manner to recommen-
dations made to report other laboratory tests used for
monitoring, e.g., tumor markers, to make clinicians
aware of changes in methods as a potential cause of im-
plausible laboratory test results (CBR2). Follow-up of
lipid profiles in a patient, from baseline to on-treatment
measurements, should ideally be performed with the
same method (and preferably in the same laboratory and
instrument) to minimize CVD-risk misclassifications
(CBR3). Values near the therapeutic decision cutpoints
should ideally be confirmed by repeated measurement(s)
(2) by the same method and then averaged (CBR4).
Are Alternative Atherogenic Lipoprotein
Measures Reliable?
CALCULATED NON-HDLC
Calculated by simply subtracting HDLC from TC, non-
HDLC represents the cholesterol in all atherogenic par-
ticles, i.e., LDL, VLDL, IDL, chylomicron remnants,
and Lp(a). In contrast to LDLC, non-HDLC considers
the atherogenic potential of remnant lipoproteins (19 ).
Therefore, non-HDLC provides a more comprehensive
risk estimation than does LDLC in patients with hyper-
triglyceridemia by adding VLDLC ( Remnant-C) to
LDLC (13 ).
Like LDLC, non-HDLC is managed with existing
lipid-lowering agents, and there is a direct consistent re-
lationship between the magnitude of non-HDLC lower-
ing and CHD-risk reduction (69 ). In a metaanalysis of
14 statin (n  100827), 7 fibrate (n  21647), and 6
niacin (n  4445) trials, a 1% decrease in non-HDLC
was associated with a 1% decrease of relative risk (RR) for
CHD (69 ). The estimated 1:1 relationship translated
into an RR of 0.78 (95% CI, 0.64–0.94) for a 25%
decrease in non-HDLC (69 ). In another metaanalysis of
49 statin and nonstatin trials (n  312175), the RR of
CVD per 1-mmol/L (39 mg/dL) reduction in non-
HDLC was 0.80 (0.77–0.82), which was similar to the
RR of 0.77 (0.75–0.79) with LDLC reduction (70 ). All
drugs including fibrates (except for CETP inhibitors) fit-
ted the regression line to predict RR reduction when
Table 5. Examples of interlaboratory uncertainty when plasma lipid parameters are determined by different methods.
Assay Assumed total error
Deﬁned concentration in
model patient Range of uncertainty
TC 9%a 200 mg/dL (5.2 mmol/L) 182–218 mg/dL (4.7–5.7 mmol/L)
TG 15%a 250 mg/dL (2.8 mmol/L) 212–288 mg/dL (2.4–3.3 mmol/L)
HDLC −20% to +36%b 40 mg/dL (1.0 mmol/L) 32–54 mg/dL (0.8–1.4 mmol/L)
Non-HDLC Derived from TC and
dHDLC
160 mg/dL (4.1 mmol/L) 128–186 mg/dL (3.3–4.8 mmol/L)
Measured LDLC −26% to +32%b 110 mg/dL (2.8 mmol/L) 82–145 mg/dL (2.1–3.8 mmol/L)
Estimated LDLC
(Friedewald)
Derived from TC, TG,
and dHDLC
110 mg/dL (2.8 mmol/L) 70–144 mg/dL (1.8–3.7 mmol/L)
ApoB 12%c 110 mg/dL (1.1 g/L) 97–123 mg/dL (0.9–1.2 g/L)
a Based on NCEP analytical performance criteria (41 ).
b Total error ranges observed by Miller et al. (44 ) across different dLDLC and dHDLC methods in dyslipidemic samples. The total error combines systematic bias and random
imprecision. The tables are not relevant for themonitoring of a patient by the same laboratory/method over time. In this situation, the bias remains constant and only the (inevitable)
imprecision is relevant. It will be considerably lower than the total error, at least for dHDLC and dLDLC (<10%), but not for TC, TG, and the derived measures cLDLC or non-HDLC.
c Based on AACC Lipoprotein and Vascular Diseases Division–Working Group on Best Practices assessment (38 ).
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non-HDLC was used, but not when LDLC was used
(70 ). In the REVEAL study, the CETP inhibitor anac-
etrapib fitted the regression line when non-HDLC re-
duction was applied (68 ).
These findings support the use of non-HDLC as a
target of therapy as recommended by guidelines (1–4).
The recommended targets for non-HDLC typically are
arbitrarily set 30 mg/dL (0.8 mmol/L) higher than
LDLC targets; this value assumes that the “normal”
VLDLC level associated with the fasting TG cutpoint of
150 mg/dL (1.7 mmol/L) is 30 mg/dL (0.8 mmol/L), as
estimated by the Friedewald formula (TG/5 in mg/dL or
TG/2.2 in mmol/L). Thus, a non-HDLC goal of 100
mg/dL (2.5 mmol/L) is equivalent to an LDLC goal of
70mg/dL (1.8 mmol/L) in very high-risk subjects (19 )
(Table 3). For very low or very high ranges of non-
HDLC, simple addition of a fixed term of 30mg/dL (0.8
mmol/L) is not appropriate. It may be more appropriate
to use a multiplier of 1.3, so that an LDLC of 2 mmol/L
is equivalent to a non-HDLC of 2.6 mmol/L (100mg/dL),
and a low LDLC of 1 mmol/L is equivalent to a non-
HDLC closer to 1.3 mmol/L (50 mg/dL) rather than
1.8 mmol/L (70 mg/dL). This is in line with the pre-
viously proposed adjustable factor for VLDLC estima-
tion based on TG and non-HDLC concentrations
(53, 54 ).
Non-HDLC can be obtained in the nonfasting state
and does not require TG to be 400 mg/dL (4.5
mmol/L) (19 ). Therefore, it is a useful alternative to
cLDLC when the Friedewald equation is invalid, essen-
tially making the need for a dLDLC assay obsolete. Al-
though non-HDLC is not dependent on TG variability,
dHDLC measurement errors in hypertriglyceridemic
samples still affect the calculation of non-HDLC.
Accuracy-based EQA surveys using the different dHDLC
assays in the calculation revealed median bias of 10%
for all methods, as compared with the expected non-
HDLC value based on TC and HDLC reference mea-
surements, although the range of individual laboratory
biases reported was broad in moderate to severe hypertri-
glyceridemic serum samples (47, 48 ). Therefore, not
only calculated LDLC but also non-HDLC values must
be interpreted with caution when making treatment de-
cisions for individuals with dyslipidemia (Table 5). How-
ever, in samples from those with moderate hypertriglyc-
eridemia in the 200 to 399 mg/dL (2.3–4.5 mmol/L)
range, non-HDLC calculated with different dHDLC as-
says showed much better concordance with CVD risk
classification according to NCEP non-HDLC cutpoints
(overall misclassification range, 0%–14%) than either
dLDLC or cLDLC test results according to LDLC cut-
points (overall misclassification range, 7%–37%) (66).
Consequently, under conditions of high TG when cLDLC
is likely to be inaccurate, non-HDLCcanbe calculated.The
Fig. 2. Example of potential confounding of negative mea-
surement bias and between-laboratory imprecision in the
clinical interpretation of LDLC concentration.
In this example, LDLC is measured with a certain assay method
in different laboratories and with the reference method
-quantiﬁcation (“true” LDLC) in a patient with very high risk (de-
sirable LDLC concentration, <70 mg/dL; 1.8 mmol/L). With LDLC
measured in laboratories using this type of assay, it will be falsely
concluded that the patient is at goal and can be excluded from
LDLC-lowering therapy. The negative bias of this assay method
compared with -quantiﬁcation is in the same range as can be
observedwith a low-potency therapeutic effect, e.g., ezetimibe, or
nutraceutical effect. To convert LDLC to mmol/L, divide value in
mg/dL by 38.6.
Fig. 3. Potential confounding of biased LDLCmeasurement
in the estimation of CVD risk reduction.
Estimated CVD risk reduction in study populations is based on the
Cholesterol Treatment Trialists’ metaanalysis of LDLC-lowering tri-
als. Measurement bias up to −0.5 mmol/L (−20 mg/dL) can be
falsely interpreted as a 10% CVD risk reduction when discordant
LDLC assay methods are used from baseline to on-treatment
measurements.
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benefit of non-HDLC over dLDLC may arguably be cost,
as it can be calculated at no additional expense above con-
ventional lipid testing.
LDL PARTICLE NUMBER
LDL can be subfractionated by NMR spectroscopy,
density-gradient ultracentrifugation, electrophoresis, ion-
mobility analysis, or chromatography (71, 72 ). NMR
spectroscopy is by far the least labor-intensive method
(72 ). NMR spectroscopy provides rapid quantification
of size and concentration (LDLP) of LDL particles and
various lipoprotein subclasses, including VLDL, IDL,
LDL, and HDL; Lp(a) is typically included in the mea-
sured LDL fraction with NMR. Lipoproteins are ana-
lyzed by NMR according to the spectral signals produced
by the terminal methyl groups contained within the lipid
particles. The number of methyl groups present in TG,
cholesterol, and phospholipids is consistent for particles
of a given size, allowing for translation into particle con-
centration (72 ). Nonetheless, this technology has not
been exhaustively standardized to account for the wide
compositional variability occurring in neutral core lipids
in different dyslipidemic conditions; therefore, caution is
warranted in data interpretation under these conditions.
NMR lipoprotein analyses have been evaluated against
other existing technologies to determine numbers, size,
and subclasses of lipoprotein particles, but the results
agree poorly with each other, in part because the various
techniques measure different physical properties (71, 73).
However, even different NMR methods yield discrepant
results, as the algorithms to decipher the NMR signals are
proprietary developments of each provider (74). Therefore,
standardization of NMR spectral analysis is urgently
needed, as well as harmonization to a unique reference ma-
terial to allow comparability of NMR data with other sub-
fractionation techniques (72).
Regardless, multiple large prospective cohort studies
that have monitored clinical outcomes, including EPIC-
Norfolk, Framingham Offspring, Multi-Ethnic Study of
Atherosclerosis (MESA), and Women’s Health Studies
have demonstrated that LDLP is superior to LDLC in
predicting CVD, consistent with the fact that many in-
dividuals with atherogenic dyslipidemia have increased
numbers of LDLP without having high LDLC (75–79);
in this situation, patients often have higher concentra-
tions of TG-rich lipoproteins, which may explain the
higher CVD risk rather than high LDLP numbers per se.
LDLP also appears to be a better indicator of subclinical
CVD because it associates more strongly with coronary
artery calcium and carotid intima–media thickness than
LDLC or non-HDLC (80 ). Whereas earlier studies em-
phasized the atherogenicity of small LDL particles, we
now know that all LDL particles are atherogenic (81 ), as
evidenced by patients with familial hypercholesterolemia
who display a predominance of large, buoyant LDL par-
ticles and early atherosclerosis (82 ). Thus, the primary
focus of patient treatment should remain the reduction of
the number (concentration) of LDL particles, without
efforts to distinguish between large and/or small LDL
particles. Indeed, a review of 24 studies that reported
relationships between LDL subfractions and cardiovas-
cular outcomes concluded that higher LDLP but not
LDL size was consistently associated with increased risk
of CVD events (83 ).
A major impediment to LDLP testing is its limited
availability outside the US, although it is offered by some
larger reference laboratories and a small automatedNMR
analyzer (Vantera) has been developed by Liposcience
(now LabCorp) for high-throughput clinical laboratory
testing (84 ). Another potential barrier is its cost, which is
about twice that of a standard lipid panel, although it
does provide additional information on other lipoprotein
fractions. NMRquantification of VLDL particle concen-
tration (VLDLP) revealed that the smallest remnant sub-
class concentration was associated with a 68% per SD
(HR, 1.68; 95% CI, 1.28–2.22) increase in residual risk
among statin-treated patients with low LDLC (85 ). The
use of LDLP and VLDLP subclass monitoring as an ad-
ditional treatment target beyond LDLC needs more
widely accessible and standardized assays in clinical lab-
oratories before it can be recommended for routine clin-
ical practice.
APOLIPOPROTEIN B
ApoB is the structural protein for all non-HDL lipopro-
teins andmodulates the centrifugal and centripetal trans-
portation of lipoproteins with reference to liver, intes-
tine, and peripheral tissues (36 ). There are 2 isoforms of
apoB: the full-length form of apoB, apoB100 with a mo-
lecular mass of 550 kDa, the major isoform synthesized
in hepatocytes and found in VLDL, IDL, LDL, and
Lp(a); and a truncated form, apoB48, with a molecular
mass of 265 kDa (48% of the molecular weight of
apoB100), that is synthesized in intestinal enterocytes
and is the structural protein of chylomicrons and chylo-
micron remnants (36 ). ApoB100, but not apoB48, con-
tains the ligand that binds to the LDL receptor. Because
each atherogenic particle contains 1 molecule of apoB,
concentrations of apoB are considered to be a direct mea-
sure of the total number of atherogenic lipoproteins in
the circulation (36 ).
Because of its relatively high abundance, apoB100
can be readily measured by immunoassays. Immunotur-
bidimetric and immunonephelometric assays are com-
mercially available on commonly used automated sys-
tems from several manufacturers. Most immunoassays
detect both apoB100 and apoB48, depending on the
specificity of the antibodies used, which are typically gen-
erated against apoB100. In fasting samples, 90% of
apoB in plasma is apoB100. Because of the longer half-
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life of LDL (3 or 4 days) compared with VLDL (3 or 4 h),
almost all of it is associated with LDL when TG concen-
trations are200 mg/dL (2.3 mmol/L) (36 ). Therefore,
at low TG concentrations, the measurement of apoB is
essentially an estimate of LDL–apoB concentration or
LDLP. Simple apoB testing obviates the need for more
expensive technologies such as NMR spectroscopy to
measure LDLP, although apoB cannot substitute for
NMR-based particle size measurements (38 ). LDLP can
be directly compared with apoB100 measurements by
adding VLDLP to LDLP and converting nanomoles per
liter (nmol/L) to mass units (mg/dL) and by multiplica-
tion by the factor 0.055 based on the molecular weight of
apoB100 (550 kDa) (38 ). This conversion recognizes
that both apoB100 and LDLP measurements include
IDL and Lp(a), in addition to LDL (38 ).
From an analytical viewpoint, apoB100 is a clearly
defined protein. Its measurement can be standardized
because of the availability of serum-based IFCC/WHO
SP3–08 secondary reference material, value-assigned us-
ing immunonephelometry and the primary reference
material—a stable LDL fraction prepared by ultracentrif-
ugation (density, 1.030–1.050 g/mL) that excludes IDL
and Lp(a) (86 ). ApoB100 measurements are easily auto-
mated and yield more accuracy compared with direct
assays for LDLC or HDLC, although concerns about the
accuracy of apoB immunoassays still exist by comparison
with apoB concentrations derived from NMR and verti-
cal autoprofile ultracentrifugation in subjects with hyper-
triglyceridemia (87 ). Uniform calibration has reduced
between-laboratory variability (CV) of apoB immunoas-
says from19% to approximately 7% to 9% (88 ). In the
EQA program in the Netherlands, 28% of participating
laboratories exceeded the NCEP bias recommendation
for apoB (6%), whereas 68% exceeded the recommen-
dation for LDLC (4%) (88 ). Notwithstanding the
availability of internationally recognized reference sys-
tems, more efforts from in vitro-diagnostic industry and
laboratory professionals have the potential to further im-
prove apoB standardization and precision to approxi-
mately 2% to 4% (88 ). Far higher than the maximum
allowed TG concentration of 4.5 mmol/L (400 mg/dL)
for cLDLC, most turbidimetric and nephelometric
apoB100 immunoassays allow TG up to at least 10
mmol/L (880 mg/dL) without interference; a TG con-
centration above this limit in nonfasting blood samples is
seen in only approximately 0.1% of individuals in the
general population (24 ).
More recently, LC-MS/MS-based quantification of
apolipoproteins has been introduced (89, 90 ). Auto-
mated mass spectrometry enables precise measurements
of apoB100 (total CV, 2.5%–4%) that are interchange-
able with immunoturbidimetric assays in both nor-
motriglyceridemic and hypertriglyceridemic sera with
TG 20 mmol/L (1770 mg/dL) (90 ). However, the
clinical applicability and throughput of these LC-
MS/MS assays are limited by the complexity and process-
ing time of the sample preparation that is typically
performed before protein measurement. With improve-
ments in the work flow using automation and shorter
chromatographic run times, LC-MS/MS protein assays
may be translated to large clinical studies and eventually
to regular clinical laboratory operations. Another advan-
tage of LC-MS/MS is that it enables the simultaneous
(multiplexed) measurement of multiple apolipoproteins
in a single run of the assay, thus making it possible to
achieve a complete apolipoprotein profile in the patient.
In the case of VLDL-associated apolipoproteins apoC-I,
apoC-II, apoC-III, and apoE, standardized clinical im-
munoassays are generally not available, which impedes
discovery of pathophysiological clues (e.g., apoC-II defi-
ciencies or apoC-III increases) for adequate diagnosis and
management of dyslipidemia. Mass spectrometry-based
proteomics revealed strong associations of VLDL-
associated apolipoproteins with incident CVD in the
prospective Bruneck Study population, which supports
the concept of targeting TG-rich lipoproteins to reduce
risk of CVD (91 ).
The use of traceable serum-based calibrators will im-
prove interlaboratory reproducibility of LC-MS/MS
methods andmay contribute to amore rapid transition of
biomarker discovery to clinical utility to identify person-
alized treatment opportunities for dyslipidemia in CVD
patients. For this purpose, the IFCC Scientific Division
established a working group in 2017 to achieve standard-
ization of a panel of the clinically relevant serum apoli-
poproteins A-I, B, C-I, C-II, C-III, E, and apo(a), and to
develop an LC-MS/MS-based reference measurement
system for the aforementioned analytes that are unaf-
fected by genetic variants, posttranslational modifica-
tions, and other factors.
PREANALYTICAL ADVANTAGES OF apoB
In addition to analytical variability, biological within-
subject (intraindividual) variability should be considered.
The average biological variability (intraindividual CV) of
apoB is 6% to 7% (range, 3%–12%), making repeated
measurements of apoB in the single patient more reliable
than calculation of non-HDLC because the latter in-
cludes the biological variations of both TC (6% CV,
range 2%–12%) and HDLC (7% CV, range 2%–14%)
(92 ). The intraindividual CV of TG (average, 28%) is a
major contributor to the overall variability of cLDLC
and ranges widely to as high as 75% (92 ). This presents a
major advantage when testing apoB or non-HDLC,
which are not affected by biological variation in TG.
Similar to non-HDLC, fasting is never required for
apoB measurement. Although each chylomicron and
chylomicron remnant particle contains 1 molecule of
apoB48, this does not present a problem in the apoB
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immunoassay. Except for type III hyperlipoproteinemia
(dysbetalipoproteinemia), there are so few chylomicron
and chylomicron remnant particles, even compared with
VLDL particles, that they do not appreciably influence
total apoB concentrations (13, 36 ). Even at peak post-
prandial concentrations, the number of chylomicron–
apoB48 particles in healthy individuals is usually 1%
and the number of VLDL–apoB100 particles is10%of
the number of LDL–apoB100 particles (36 ). Thus, even
if the number of chylomicrons increases 5- to 10-fold, no
substantial changes will occur in total apoB concentra-
tion. In contrast, the contribution of Lp(a)–apoB100 to
apoB concentration can be substantial (10%) among
individuals with very high Lp(a) 100 mg/dL (93 ).
Considering that apoB100 contributes approximately
16% of Lp(a) mass, Lp(a)-corrected apoB concentration
can be estimated as apoB (mg/dL)  [Lp(a) (mg/dL) 	
0.16] (93 ).
Consensus-based recommendation. Non-HDLC and apoB
tests are more accurate than dLDLC and cLDLC, espe-
cially for measurements in samples that are hypertriglyc-
eridemic, nonfasting, or at low LDLC concentrations.
Non-HDLC offers the advantage of adding Remnant-C
to LDLC, independent of TG variability (CBR6), but is
still compromised by nonspecificity bias of dHDLC used
in the calculation. ApoB has the potential to meet ana-
lytical performance criteria in terms of accuracy, stan-
dardization, availability on common laboratory instru-
ments, and relatively low cost, and can be used to
estimate numbers (concentrations) of LDLP plus
remnant-P (VLDLP) and Lp(a) particle numbers, but
not size (CBR7) (38 ). Multiplex LC-MS/MS apolipo-
protein profiles or NMR-based LDLP and VLDLP sub-
class numbers and size are promising approaches for use
in personalized (precision) medicine for cardiovascular
risk management but still need standardization if labora-
tory data from several epidemiological studies and clini-
cal trials are pooled for evaluation of clinical performance
of the tests. Furthermore, wide accessibility is critical to
enable clinical use.
Should Non-HDLC or apoB Replace LDLC
Tests?
OBSERVATIONAL STUDIES IN GENERAL POPULATIONS
Studies have reported inconsistent findings as to whether
non-HDLCor apoB identifies CVD riskmore effectively
than traditional LDLC testing. A metaanalysis of 12 ep-
idemiological studies including 233 455 individuals con-
cluded that apoB, with an RR of 1.43 (95% CI, 1.35–
1.51) per 1-SD increment, was superior to non-HDLC
(1.34; 1.24–1.44) and LDLC (1.25; 1.18–1.33) in the
association with future fatal or nonfatal CVD events
(P 0.001) (94 ). In 10% of women and 20% of men in
the Copenhagen City Heart Study (n 9231) included
in this metaanalysis, apoB predicted a higher risk than
cLDLC-related risk for developing CHD (P  0.01);
these individuals had higher TG and an optimal cLDLC
concentration (95 ). However, in 4679MESA study par-
ticipants, associations of lipoprotein particle measures
(i.e., apoB and LDLP) with CHD were attenuated after
adjustment for standard lipid variables, indicating that
their measurement does not detect risk that is unac-
counted for by the standard lipid panel (96 ).
A large-scale metaanalysis performed by the Emerg-
ing Risk Factors Collaboration group on data of 302 430
patients (involving 12 785 CHD cases) from 68 prospec-
tive studies showed that adjusted HRs for CHD risk for
1-SD higher values were 1.50 (95% CI, 1.39–1.61) for
non-HDLC and 0.99 (0.94–1.05) for TG after adjust-
ment for non-HDLC and HDLC (97 ). For a subset of
44 234 participants from 8 studies with measured
dLDLC, HRs were similar for non-HDLC and dLDLC,
1.42 (1.06–1.91) and 1.38 (1.09–1.73), respectively.
HRs were at least as strong in nonfasting participants
than in those who did fast (97 ). The same group per-
formed another metaanalysis of 26 observational studies
(139 581 participants, 12 234 events) that also had infor-
mation on apolipoproteins and found similar prognostic
values: HRs per 1-SD increase for apoB and non-HDLC
were 1.24 (1.19–1.29) and 1.27 (1.22–1.33), respec-
tively (98 ). Replacement of information on TC with
various lipid parameters, including non-HDLC and
apoB, did not improve CVD prediction (98 ).
A systematic review of 9 relevant studies by the Lab-
oratory Medicine Best Practices method indicated that
addition of apoB to standard risk factors (RR  1.31;
95%CI, 1.22–1.40) resulted in significant improvement
in long-term CVD risk assessment (99 ); however, be-
cause there were an insufficient number of studies, no
conclusion was made for the effectiveness of non-HDLC
in predicting CVD events (99 ).
INTERVENTIONAL STUDIES
On-treatment apoB adds prognostic information to
LDLC and even to non-HDLC in some but not all pri-
mary prevention and secondary prevention trials. A
metaanalysis of on-treatment data from 38153 partici-
pants in 8 randomized controlled statin trials revealed
adjusted HRs per 1-SD higher of 1.13 (95% CI, 1.10–
1.17) for LDLC, 1.16 (1.12–1.19) for non-HDLC, and
1.14 (1.11–1.18) for apoB (100 ). All 3 were generally
similar inmagnitude of CVD residual risk, although only
the small difference between LDLC and non-HDLCwas
statistically significant (P  0.002), whereas the differ-
ence between LDLC and apoB was not significant (100 ).
Changes in non-HDLC also explained a larger propor-
tion (64%) of the statin-induced atheroprotective effect
than did LDLC (50%) or apoB (54%) (100 ). It should
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be noted thatmost of the studies included in themetaanaly-
sis used heparin-Mn2 precipitation for HDLC measure-
ment, which differs from direct assays mostly used nowa-
days; therefore, these results based on non-HDLCmay not
translate to current clinical laboratory practice.
A larger metaanalysis of 25 trials conducted in
131 134 patients including 12 on statin, 4 on fibrate, 5
on niacin, and 2 on simvastatin-ezetimibe, came to sim-
ilar conclusions using Bayesian random-effect analysis:
Non-HDLC was slightly superior to apoB for prediction
of CHD (Bayes factor, 1.45) and CVD (Bayes factor,
2.07) (101 ). Only the combination of apoB with non-
HDLC or LDLC slightly improved CVD risk prediction
(Bayes factor, 1.13). Combining the 25 trials, each 10-
mg/dL decrease in apoB was associated with a 9% de-
crease in CHD, no decrease in stroke, and a 6% decrease
in major CVD risk (101 ). In the JUPITER trial in adults
without diabetes or CVD, with baseline cLDLC 130
mg/dL (3.4 mmol/L) and C-reactive protein concentra-
tions 2 mg/L, standardized HRs did not differ for on-
statin cLDLC, non-HDLC, and apoB: 1.31 (95% CI,
1.09–1.56), 1.25 (1.04–1.50), and 1.27 (1.06–1.57),
respectively (102 ). Interestingly, in the JUPITER trial,
baseline apoB, LDLP, VLDLP, Remnant-C, and non-
HDLC were all associated with increased CVD risk,
whereas cLDLC was not (85 ).
In another metaanalysis, the mean CHD risk reduc-
tion per SD decrease was higher for apoB (24%; 95%CI,
19%–29%) compared with 20% (16%–24%) for LDLC
and 20% (15%–25%) for non-HDLC across 7 major
statin trials (103 ). Within each trial, risk reduction per
change in apoB averaged 22% (12%–31%) greater than
changes in LDLC and 24% (22%–26%) greater than
changes in non-HDLC (P  0.001). In the same meta-
analysis, 1-SD decreases to equivalent target concentra-
tions of LDLC (42%), non-HDLC (41%), and
apoB (42%) would yield expected risk reductions of
30%, 32%, and 39%, respectively, suggesting that ben-
efit would be greater if therapy were targeted to apoB
rather than to LDLC or non-HDLC (103 ).
Consensus-based recommendation. Metaanalyses among
study populations suggest that the clinical perfor-
mance of non-HDLC and apoB, although superior to
LDLC in some studies, is, on average, comparable
with LDLC to predict risk. However, in a subset of
individuals in whom apoB or non-HDLC is high de-
spite a normal or low LDLC, CVD risk tracks with
apoB or non-HDLC (CBR8).
Should Non-HDLC or apoB Be Used as
“Add-on” Tests to LDLC?
Although there is high overall correlation and equivalent
predictive power in large population-based studies and
trials, data from concordance/discordance analyses reveal
that the addition of non-HDLC or apoB to LDLC has
the potential to improve risk prediction by identifying
more high-risk individuals in a personalized approach.
Discordances (1 normal, the other high) exist between
LDLC and non-HDLC, LDLC and apoB, and non-
HDLC and apoB, and may be present in up to 25% of
the general population (Fig. 4).
LDLC VS NON-HDLC
Despite the correlation between non-HDLC and either
cLDLC or dLDLC measurements in study populations,
it is evident that non-HDLC and LDLC do not consis-
tently provide the same clinical information in individual
patients. Among individuals with the same non-HDLC
value, there can be a 40- to 60-mg/dL (1.0–1.6 mmol/L)
difference in cLDLC, depending on the range of TG
concentrations between 100 and 300 mg/dL (1.1–3.4
mmol/L) (104). The correlation between non-HDLC
and dLDLC significantly decreases with increasing TG
concentrations: In a study of 1590 patients, the percent-
age of patients with non-HDLC concentration above the
guideline-based cutpoint of 130 mg/dL (3.6 mmol/L),
despite having dLDLC concentration on target at100
mg/dL (2.6 mmol/L), increased significantly with in-
creasing TG (105 ). Replacing dLDLC with non-HDLC
as a therapeutic target in hypertriglyceridemic patients
almost doubled the number of patients requiring treat-
ment (105 ).
In a large database of lipid profiles of 1 310 440 pa-
tients, non-HDLC reclassified a significant proportion of
patients to a higher guideline-based treatment category
compared with cLDLC, especially at low LDLC in the
treatment range and at TG 150 mg/dL (1.7 mmol/L)
(106 ). Of patients with LDLC70mg/dL (1.8 mmol/L),
15% had non-HDLC 100 mg/dL (2.6 mmol/L) and
22%had this value if TG concentrations were 150 to 199
mg/dL (1.7–2.3 mmol/L) concurrently (106 ). Similarly,
of patients with LDLC concentrations between 70 and
99 mg/dL (1.8 and 2.6 mmol/L), 12% had non-HDLC
130 mg/dL (3.4 mmol/L) and 17% had this value if
TG concentrations were concurrently 150 to 199 mg/dL
(1.7–2.3 mmol/L), and discordance between LDLC and
non-HDLC percentiles increased at lower LDLC and
higher TG concentrations (106 ).
The potential clinical implications of discordant
LDLC and non-HDLC are most evident at normal or
low LDLC concentrations. Among apparently healthy
individuals with cLDLC 100 mg/dL (2.6 mmol/L) in
the EPIC-Norfolk prospective population study (n 
21448), those with non-HDLC 130 mg/dL (3.4
mmol/L) had an HR for future CHD of 1.84 (95% CI,
1.12–3.04) compared with those with non-HDLC
130 mg/dL (3.4 mmol/L) (107 ). The risk associated
with a 1-SD increase of non-HDLC (HR  1.54; 95%
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CI, 1.35–1.74) was higher than the risk associated with a
1-SD increase of cLDLC (HR 1.22; 1.17–1.27) or TG
(HR 1.14; 1.09–1.19). The higher risk associated with
increased non-HDLC was present at any category of
LDLC concentrations, and particularly at low LDLC
concentrations, whereas LDLC did not provide any ad-
ditional risk to non-HDLC for CHD (107 ). This notion
implies that there is no reason to use non-HDLC as an
“add-on” test: If concordant, it performs equally as well
as LDLC. If discordant, it performs better. This implies
that the net result is an overall better performance of
non-HDLC compared with LDLC.
The same reflection is applicable to the metaanalysis
by Boekholdt et al. of 8 statin trials (100 ). In this analysis,
HRs for major CVD risk were calculated for 4 categories
of 38 153 treated patients based on whether they reached
the LDLC target of 100 mg/dL (2.6 mmol/L) and the
non-HDLC target of 130 mg/dL (3.4 mmol/L) (100 ).
Statin-treated patients reaching the non-HDLC target
but not the LDLC target had an HR of 1.01 (95% CI,
0.92–1.12) compared with those reaching both targets.
Patients reaching the LDLC target but not the non-
HDLC target had an HR of 1.32 (1.17–1.50) (100 ).
These data suggest that calculation of non-HDLC is
at least equally good at predicting CHD as compared
with measurement or calculation of LDLC in the overall
population, and may be superior to LDLC if discordant
in individuals with high TG because it includes VLDLC
( Remnant-C). The only concern is the selection of the
cutoff value: It may be themore sensitive risk cutpoint for
non-HDLC as compared with LDLC rather than the
biomarker that makes the difference. Guideline-based
non-HDLC cutpoints have been arbitrarily defined by
consensus of expert groups and societies, based on the
assumption that a normal VLDLC concentration exists
when TG are150 mg/dL (1.7 mmol/L), which is30
mg/dL (0.8 mmol/L) as estimated by the Friedewald for-
mula. Lowering non-HDLC cutpoints leads to upward
reclassification of patients (if the goal is to reduce under-
treatment), and higher cutpoints lead to downward re-
classification (if the goal is to reduce overtreatment). Risk
cutoff values need to be validated for diagnostic perfor-
mance. For present purposes, the combination of non-
HDLC with cLDLC data seems an appropriate strategy
to guide therapy. This may compensate for the underes-
timation or overestimation of LDLC in terms of clinical
decision-making, given the uncertainty of the measure-
ment or calculation when LDLC approaches 70 mg/dL
(1.8 mmol/L). Utilizing non-HDLC, at no additional
expense, appears to be preferable to dLDLC when
cLDLC is not available because of an invalid Friedewald
equation (CBR9). However, the compromised accuracy
of dHDLC assays in samples with hypertriglyceridemia
reduces the benefit in reporting non-HDLC in some in-
dividuals (48 ).
Fig. 4. Relative LDL particle size and number and Remnant-C in 3 patientswith identical low LDLC (70mg/dL; 1.8mmol/L) butwith
discordant non-HDLC and apoB with regard to desirable treatment targets for very high-risk patients.
Patient 1 has all 3 targets at goal and normal numbers of (predominantly larger sized) LDL particles. Patient 2 with moderate hypertriglycer-
idemia has discordant non-HDLC above target (100 mg/dL; 2.6 mmol/L) because of increased Remnant-C. Patient 3 also has moderate
hypertriglyceridemia and increased Remnant-C but concurrently higher apoB concentration than patient 2 because of a high number of small
dense LDL particles not detected by standard LDLC measurement.
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LDLC VS apoB
The implication of discordant apoB vs LDLC is most
evident in patients with atherogenic dyslipidemias, who
present with “normal” concentrations of TC and
LDLC—a profile that is especially prevalent among in-
dividuals with the metabolic syndrome or insulin resis-
tance and in those taking medications, such as statins,
that reduce LDLC more than apoB (108 ). In 1522 indi-
viduals in the Insulin Resistance Atherosclerosis Study,
increased apoB with normal cLDLC in each NCEP
Adult Treatment Panel III risk category was more
strongly associated with risk factors including abdominal
obesity, dyslipidemia, hyperinsulinemia, and thrombosis
than increased cLDLC with normal apoB (109 ), consis-
tent with the notion that cardiovascular risk is more di-
rectly related to the number of apoB-containing particles
(reflected by apoB measurement) than to the cholesterol
content of lipoproteins (81 ). Therefore, risk may be un-
derestimated on the basis of TC and LDLC alone in
subjects with predominant small, cholesterol-depleted
LDL particles, whereas increased apoB concentration
helps identify these high-risk individuals whowould have
otherwise been overlooked because of their “optimal”
LDLC, a situation estimated to apply to approximately
30% of the population (108 ).
For example, when evaluating a patient with diabe-
tes and an LDLC of 90 mg/dL (2.3 mmol/L), it is often
concluded that they are at goal because their LDLC is
100 mg/dL (2.6 mmol/L) (1 ). However, this level rep-
resents higher numbers of cholesterol-poor LDL particles
and puts the patient at higher risk compared with a per-
son with an LDLC of 90 mg/dL (2.3 mmol/L) but with-
out atherogenic dyslipidemia and associated insulin resis-
tance. Another problem is that these patients tend to have
increased concentrations of TG-rich lipoproteins, and by
the Friedewald equation, their LDLC will be underesti-
mated (57, 58 ).
The discordance analysis of the Women’s Health
Study (110 ) represents a comprehensive comparison of
atherogenic lipoprotein markers. Despite significant
LDLC correlations with non-HDLC, apoB, and LDLP
observed in the 27 533 study participants, prevalence of
LDLC discordance as defined by median cutpoints was
12%, 19%, and 24% for non-HDLC, apoB, and LDLP,
respectively. Among women with dLDLC less than the
median (121 mg/dL; 3.1 mmol/L), CHD risk was un-
derestimated 3-fold for those with discordant (the me-
dian or more) non-HDLC (HR 2.92; 95% CI, 2.33–
3.67), apoB (HR 2.48; 2.01–3.07), or LDLP (HR 
2.32; 1.88–2.85) compared with women with concor-
dant concentrations; these individuals had increased TG,
low HDLC, and smaller LDL particles that were
cholesterol-depleted (110 ). Conversely, among women
with dLDLC equal to the median or more, risk was over-
estimated 3-fold for those with discordant (less than the
median) non-HDLC (HR  0.40; 0.29–0.57), apoB
(HR 0.34; 0.26–0.46), or LDL-P (HR 0.42; 0.33–
0.53); these individuals had increased LDLC because
their LDL particles were larger and more cholesterol-
enriched, despite having fewer overall numbers of LDLP
or apoB (110 ).
Additional analysis with cLDLC instead of dLDLC
revealed that, among women with cLDLC below me-
dian, HRs for discordant apoB or LDLP were increased
(110 ). In a recent discordance analysis among 2794
young adults, high apoB and low cLDLC or non-HDLC
discordance was associated with higher odds of develop-
ing coronary artery calcium in midlife: adjusted odds
ratios [OR (95% CI)] were 1.55 (1.10–2.18) and 1.45
(1.01–2.09), respectively (111 ). Discordance analyses of
cLDLC vs LDLP in the Framingham and MESA studies
both favored LDLP over cLDLC among discordant in-
dividuals (75, 79 ).
These data suggest that for most individuals with
concordant values of LDLC and an alternative measure
(non-HDLC, apoB, or LDLP), the clinical performance
of these measures is similar. However, among the sub-
group of individuals (up to 25% of the Women’s Health
Study population) with discordance of LDLC with alter-
native measure, risk may be overestimated or underesti-
mated when one relies on LDLC alone (110 ). If apoB
performs either equally well (if concordant) or better (if
discordant) than LDLC, the 2-step procedure is redun-
dant, and apoB could be the single test rather than an
add-on test.
NON-HDLC VS apoB
Non-HDLC is not a clinically accurate surrogate for
apoB because the 2 markers represent different measures.
Non-HDLC and apoB are highly correlated in large
population-based studies but only moderately concor-
dant between individuals (108 ). At any non-HDLC
value, there is considerable variation in apoB concentra-
tions ranging from far above to far below the desirable
values (112 ). Such discordance between non-HDLC and
apoB is even more pronounced in patients with hypertri-
glyceridemia, particularly familial combined hyperlipid-
emia, which is characterized by hyper-apoB (37 ), and
dysbetalipoproteinemia owing to the apoE2/2 genotype,
which typically presents with low apoB concentration
(and positively discordant non-HDLC with regard to
apoB) because the -VLDL remnants are not processed
to LDL particles (37 ). None of those dyslipidemias can
be characterized with non-HDLC (112 ).
Beyond LDLC, non-HDLC estimates the impact of
2 closely related metabolic biomarkers of atherogenic
dyslipidemia, namely, (VLDL) remnant cholesterol and
LDL particle number, but it does not accurately measure
the latter. If LDL particles are cholesterol-depleted, as
observed in atherogenic dyslipidemia, LDLC and non-
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HDLC will underestimate the risk because of high LDL
particle numbers (and consequently, discordant high
apoB concentration) (112 ). Also, the mass of cholesterol
within VLDL particles is highly variable. VLDL– and
IDL–apoB100 make up a relatively small fraction
(10%) of total plasma apoB, whereas VLDLC can eas-
ily range from 10% to 25% or more of non-HDLC, with
the result that there is much greater variance in VLDLC
as a percentage of non-HDLC than there is of VLDL–
apoB100 as a percentage of total apoB (108 ).
Discordance analysis of apoB vs non-HDLC in the
INTERHEART case–control study demonstrated that
apoB is not equivalent to non-HDLC in predicting CVD
risk (113 ). The OR for cases to controls with a “non-
HDLCapoB phenotype” (cholesterol-enriched apoB
particles) was 0.72 (95% CI, 0.67–0.77), indicating risk
was less than the reference concordant group, whereas the
OR for the “non-HDLCapoB phenotype” (cholesterol-
depleted apoB particles) was 1.58 (1.38–1.58), indicating
risk was significantly greater than the concordant group
(113).
In the Insulin Resistance Atherosclerosis Study (n
1522), despite lower LDLC, the hyper-apoB group with
normal non-HDLC had increased risk indicated by
greater waist circumference, hyperinsulinemia, and lower
insulin sensitivity (114). ApoB was more closely associ-
ated with central adiposity, insulin resistance, and in-
flammation than non-HDLC, suggesting that apoB is a
better risk parameter than non-HDLC for identifying a
subgroup of individuals with or without metabolic syn-
drome with increased cardiovascular risk (114). Once
apoB concentrations are increased, thenCHD risk can be
considered high and non-HDLC yields negligible addi-
tional risk prediction.
Among 18 225 men in the Health Professionals
Follow-up Study, non-HDLC and apoB were both
strong predictors of CHD,more so than LDLC (115 ). In
this male cohort, the RR of CHD (top vs bottom quin-
tile) was 3.01 (95% CI, 1.81–5.00) for apoB, 2.76
(1.66–4.58) for non-HDLC, and 1.81 (1.12–2.93) for
dLDLC. When non-HDLC and dLDLC were mutually
adjusted, only non-HDLC was predictive of CHD.
When non-HDLC and apoB were mutually adjusted,
only apoB was predictive. Within each tertile of non-
HDLC, the risk of CHD increased with increasing ter-
tiles of apoB, whereas within each tertile of apoB, the risk
did not increase by tertiles of non-HDLC. Values for TG
concentrations added significant information to non-
HDLC but not to apoB for CHD risk prediction (115 ).
In theWomen’s Health Study (n 27533), discor-
dance among apoB, LDLP, and non-HDLC occurred in
up to 20% of women (116 ). Women with discordant
high particle concentrationmeasured by apoB and LDLP
were more likely to have metabolic syndrome and diabe-
tes. Women with high particle concentration relative to
non-HDLC had increased CHD risk: Age-adjusted HR
was 1.77 (95%CI, 1.56–2.00) for apoB and 1.70 (1.50–
1.92) for LDLP. After adjustment for clinical risk factors
including metabolic syndrome, these risks attenuated to
1.22 (1.07–1.39) for apoB and 1.13 (0.99–1.29) for
LDLP. Importantly, most of these individuals with dis-
cordant high apoB or LDLP would be missed (deemed
very low risk) by global risk algorithms (2 ). Discordant
low apoB or LDLP relative to non-HDLC was not asso-
ciated with lower risk (116 ).
The relative merits of apoB vs non-HDLC have
been a point of ongoing debate and controversy. Both
offer the practical benefits of assessment independent of
the prandial state. Although apoBmeasurement comes at
an extra cost, the findings from discordance analyses sup-
port our consensus that in certain patients the number of
atherogenic lipoprotein particles measured by apoB (or
LDLP) is more predictive of development of CHD than
the cholesterol carried by these particles, measured by
non-HDLC. It should be noted, however, that apoB and
LDLP measurements may not always be equivalent in
their ability to predict CVD risk. A metaanalysis in 2013
including 25 clinical studies revealed 21% discordance of
apoB immunoassays and NMR-based LDLP measure-
ments in their associations with diverse clinical out-
comes, and the strength of association (as indicated by
OR, RR, and HR) was more often higher for LDLP than
it was for apoB (38 ).
ON-TREATMENT DISCORDANCES
The reduction of LDLC, non-HDLC, and apoB concen-
trations achieved with statin therapy displays large intra-
individual variation, even at very low LDLC70 mg/dL
(1.8 mmol/L), as observed in a metaanalysis of 8 statin
trials (117 ). Statins lower LDLC and non-HDLC signif-
icantly more than they lower apoB or LDLP (118 ). This
is because statins lower larger cholesterol-rich LDL par-
ticles proportionately more than they do for smaller
cholesterol-poor LDL particles (119 ). A metaanalysis of
17 000 patients from 11 statin trials showed that LDLC
was reduced by 43%, non-HDLC by 39%, and apoB by
33% (118 ). This necessarily results in an on-treatment
LDLP concentration that, on average, is higher than
would be anticipated from the concurrent LDLC or non-
HDLC. However, high Lp(a) concentrations in some
patients will also help explain why apoB and LDLP
are reduced less than LDLC or non-HDLC. The average
on-treatment LDLC is reduced to the 20th percentile
and non-HDLC to the 29th percentile, but apoB and
LDLP decrease only to the 55th and 51st percentile of the
population, respectively (120 ). This discordance points
to substantial residual risk in many statin-treated patients
and the opportunity for further benefit of LDL-lowering
therapy that is lost if apoB or LDLP is not measured. In the
AFCAPS/TexCAPS trial, on-treatment apoB maintained
Special Report
1024 Clinical Chemistry 64:7 (2018)
its strong risk relationshipwithmajor coronary events after 1
year of lovastatin therapy, whereas LDLC lost statistical sig-
nificance (121). Residual risk is also associated with on-
treatment non-HDLCandmore prominentlywith concen-
trations of smaller VLDLP, which may represent remnants
of TG-rich lipoproteins that are insufficiently reduced by
LDL-targeted statin dosages (85, 119, 122).
A large proportion of treated patients achieving their
LDLC and even non-HDLC goals fail to meet their apoB
target without more aggressive therapy (123–125). In the
US National Health and Nutrition Examination Survey
2009–2010, 64% of statin-treated adults were at goal for
LDLCand63%were at goal for non-HDLC,but only 52%
were at goal for apoB (126). Among those at goal for non-
HDLC, 50% of those with CHD and 33% of other high-
risk adults (including patients with diabetes and chronic
kidney disease) were not at apoB goal (126). The presence
of atherogenic dyslipidemia is associatedwith failure tomeet
all 3 targets of LDLC 70 mg/dL (1.8 mmol/L), non-
HDLC100 mg/dL (2.6 mmol/L), and apoB0.8 g/L,
such a nonachievement being found in a large proportion
(one-third) of very high risk type 2 diabetes patients with
on-statin LDLC70 mg/dL (1.8 mmol/L) (127).
Discordances persist with increasing intensity of sta-
tin treatment. Combined analysis of 2 randomized sec-
ondary prevention trials with statins, TNT and IDEAL,
showed that non-HDLC was reduced to the 30th per-
centile and apoB was reduced only to the 60th percentile
of the low-intensity statin group (128 ). In the high-
intensity statin group, non-HDLC was reduced to the
5th percentile, whereas apoB was reduced to only the
30th percentile (128 ). In the JUPITER trial of high-
intensity statin, 46% of treated patients showed an
LDLC reduction 50%, 28% showed non-HDLC re-
duction 50%, and only 18% showed apoB reduction
50% (7 ). It remains to be demonstrated whether in-
tensifying treatment strategies to further reduce undesir-
able apoB concentrations would yield an improvement in
outcomes. A smaller change in apoB concentrations may
not necessarily need to translate into smaller risk reduc-
tion. If 30% apoB decrease confers the same risk reduc-
tion as 50% LDLC decrease, it will not be a superior
target. To test this, one would need to compare 2 inter-
ventions that lower apoB and LDLC disproportionately
and assess the population attributable risks associated
with the changes, i.e., the number (or proportion) of
CVD cases that would not occur in a population if the
risk factor were further lowered. In the JUPITER trial,
similar relationships between percent reduction and
treatment efficacy were observed in clinical outcome
analyses focusing on LDLC, non-HDLC, or apoB (7 ).
Discordances in significant reductions in LDLC, non-
HDLC, and apoB concentrations are also observed in anti-
PCSK9 trials. Typically, PCSK9 inhibition causes av-
erage reductions of 60% to 65% in LDLC, 50% to 55%
reductions in non-HDLC, and 45% to 50% reductions
in apoB from baseline depending on PCSK9 mono-
therapy or addition to moderate- or high-intensity statin
(ezetimibe) therapies in patients with hypercholester-
olemia (129–132).
The reductions of LDLC, non-HDLC, and apoB ob-
tained with anti-PCSK9 therapy are similar in patients with
and without mixed hyperlipidemia, reflecting higher circu-
lating concentrations of TG and remnant-like lipoproteins.
Efficacy analysis of 3146 participants in 4 studies of evoloc-
umab showed that the mean percentage change from base-
line for patients with orwithout increased fastingTG150
mg/dL (1.7 mmol/L) followed a similar pattern for LDLC
(67% and65% vs placebo), non-HDLC (53% and
54%), and apoB (49% and50%) (133). A similarly
high proportion of evolocumab-treatedNCEP III high-risk
patientswith andwithout increasedTGachieved theLDLC
target of70 mg/dL (1.8 mmol/L) (82% vs 81%, respec-
tively) and 100 mg/dL (2.6 mmol/L) (92% vs 92%, re-
spectively). However, significantly more patients without
increased TG achieved the apoB target of 0.8 g/L than
those with increased TG (93% vs 85%). Additionally, sig-
nificantly more patients without increased TG achieved the
non-HDLC target of 100 mg/dL (2.6 mmol/L) than
those with increased TG (85% vs 77%), suggesting that
PCSK9 inhibition less efficiently reduces Remnant-C than
LDLC in patients with hypertriglyceridemia (133).
Consensus-based recommendation. Discordance analysis of
LDLC, non-HDLC, and apoB goals suggests opportuni-
ties to identify “hidden” CVD risk and to judge the ad-
equacy of therapy. To reach the current proposed non-
HDLC and apoB goals, novel therapies in addition to
high-dose statins would inevitably be needed to further
lower non-HDLC or apoB at very low concentrations of
LDLC; however, the evidence base for this approach is
still incomplete. The cutpoints for non-HDLC and apoB
are arbitrarily defined by consensus cutoffs and need to
be validated for diagnostic performance before they can
be used as “add-on” tests to identify and treat additional
persons at high risk. One would need to compare the
reduction inCVD events achieved at each level of LDLC,
non-HDLC, or apoB changes in the study data sets; oth-
erwise, it is not clear whether the biomarker or the cutoff
makes the difference.
For now, we recommend that every lipid profile report
should add non-HDLC (CBR5). For those who determine
TC, TG, andHDLC (and calculate cLDLC), this comes at
no extra cost, as does calculatedRemnant-C, which likewise
can be reported free of charge. To improve patient comfort
and compliance, there are advantages of this approach using
nonfasting blood samples (19).When LDLC is unavailable
owing to an invalidFriedewald equation (TG400mg/dL;
4.5 mmol/L), additional dLDLC measurement is not nec-
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essary, and non-HDLC calculation can be used instead of
cLDLC to evaluate therapeutic response (CBR9).
Which Is the Ideal Atherogenic Lipoprotein
Test?
The traditional lipid profile of TC, TG, HDLC, and
LDLC remains the primary approach for dyslipidemia
diagnosis and CVD risk categorization. The position of
LDLC is, however, challenged under treatment. The
substantial residual risk that persists in LDLC-targeted
therapies even at low LDLC 70 mg/dL (1.8 mmol/L)
has fueled the debate about the cost-effectiveness of the clin-
ical use of non-HDLC or apoB as an index of treatment
efficacy (134). Thus, although the lipid profile will remain
essential for initial diagnosis and risk categorization, one
might suggest that follow-up of lipid-lowering therapy
could be simplified and expenses reduced by calculation of
non-HDLC (by only 2 measurements of TC and HDLC)
or singlemeasurement of apoB,without the need to fast and
without regard to TG (134). Use of either non-HDLC or
apoB adds an element of simplicity to guidelines by com-
bining all “atherogenic lipoproteins” (apoB) or “atherogenic
cholesterol” (non-HDLC) into a single marker. There are,
however, significant barriers to replace LDLC by non-
HDLC or apoB as a primary biomarker for management of
dyslipidemia-related risk (135) (Table 6).
What makes a good marker of atherogenic lipopro-
teins? It should be easily measured in a nonfasting sample
with a low cost and accurate procedure, and should not
increase healthcare expenses to identify patients in whom
CVD prevention strategies or therapies will be cost-
effective. For monitoring purpose, the test should not
only be able to predict clinically significant events but
also respond to changes in the condition or treatment.
None of the present tests in question has been completely
validated according to key criteria to become a medically
useful test, as defined by the EFLMWorking Group for
Test Evaluation (136 ). Although the analytical perfor-
mance of apoB measurements is superior to measure-
ments or calculations of LDLC and even non-HDLC,
and the clinical performance of apoB testing may be of
added benefit over standard lipid assessment in selected
patients, more definitive evidence in rigorously per-
formed outcome studies is needed to confirm that apoB
testing will effectively lead to reduced CVD events (clin-
ical effectiveness) and health-economic costs (cost-
effectiveness) compared with LDLC-targeted strategies
(Table 7). These key test components should be validated
in the setting of novel therapies aiming at very low LDLC
targets 50 mg/dL (1.3 mmol/L).
A well-defined unmet clinical need should act as the
architect for biomarker test development (137 ). Desir-
able clinical performance specifications should be pre-
defined (for which rate of misclassification and/or mis-
treatment is acceptable) for each test indication because
they determine the analytical performance specifications
(136 ). Clinical studies can then be designed to evaluate
clinical and cost-effectiveness of the test to improve
health and economic outcomes (138 ). In randomized
controlled trials of diagnostic investigations, patients are
randomized to receive the new test or the standard test,
and the impact on clinical decision for detecting or treat-
ingmore patients at high risk (i.e., not detected or treated
when using the standard test) is assessed (138 ). Bio-
marker tests per se do not bear directly on health out-
comes. Investigations guide the decisions and actions of
clinicians and patients, and it is these that directly impact
on health outcomes. New tests can improve outcomes by
optimizing the selection of treatment, through more ac-
curate risk classification or prediction of CVD or CVD
outcomes (i.e., mortality, morbidity, and complication
rates), or by offering other patient benefits (i.e., more
appropriate treatment options, the impact of medical
care on patient well-being, quality of life) (138 ). Indeed,
the emerging approach of precision medicine (or person-
alized medicine) requires novel biomarkers for targeted
therapies, tailored to the individual patient’s condition.
Operational outcomes can include time to test results,
time to treatment, and other operational advantages such
as nonfasting blood sampling (19 ). Economic outcomes
include the cost of the test and all downstream conse-
quences on healthcare, such as the financial benefits of
morbidity avoided, quality-adjusted life-years gained, or
reductions in length of hospital stay (136, 138).
The use of non-HDLC, apoB, or LDLP would be
cost-effective if these tests provide information to guide
therapy to reduce the risk (and cost) of CVD events more
than standard therapy guided by LDLC alone. In 1meta-
analysis, it was estimated that a non-HDLC targeting
strategy would prevent approximately 300 000 more
CVD events than an LDLC strategy, whereas an apoB
strategy would prevent approximately 500 000 more
events than a non-HDLC strategy in the US adult pop-
ulation over a 10-year statin treatment period (94 ). Re-
cent studies on the cost-effectiveness of LDLP-guided
statin therapy, either alone or in combination with
LDLC, showed potential cost-saving because of reduc-
tions in medical expenses from fewer CVD events, and
this approach was estimated to increase quality-adjusted
life-years compared with standard LDLC-alone treat-
ment (139–141). LDLP-guided therapy was expected to
result in LDLC reductions that exceed those guided by
LDLC alone because of the use of higher doses of statins
to achieve LDLP goals (139–141). With the availability
of inexpensive generic statins, the cost-effectiveness of
intensifying pharmacological intervention aiming to re-
duce non-HDLC, apoB, or LDLP will be enhanced.
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Consensus-based recommendation. The ideal biomarker(s)
of atherogenic lipoproteins should be validated for ana-
lytical performance, clinical performance, clinical effec-
tiveness, and cost-effectiveness to justify its/their use in
clinical practice in different well-defined settings:
screening, dyslipidemia diagnosis, treatment choice,
and follow-up. For now and until these issues are clar-
ified, non-HDLC is the best choice, as it incurs no
additional expense to the patient or health system. A
cost-efficient approach is to measure 3 markers (TC,
TG, HDLC) and to calculate cLDLC and non-
HDLC. Clinical laboratories should proactively calcu-
late and report non-HDLC together with cLDLC on
all lipid profiles (CBR5) (142 ).
Conclusion
The principal aim of laboratory medicine is to provide a
high-quality service that delivers unequivocal test infor-
mation and improves patient outcomes across the con-
tinuum of care. Laboratory medicine is a key component
of models of care for all types of lipid disorders (142).We
have provided CBRs for improving the use of the lipid
profile to assess CVD risk conferred by atherogenic lipo-
Table 6. Strengths, weaknesses, opportunities, and threats (SWOT analysis) of LDLC, non-HDLC, apoB, and LDLP.
LDLC Non-HDLC apoB LDLP
Strengths
Widely available laboratory
assays for dLDLC
measurement or cLDLC
calculation
Clinical performance: strong
evidence-based, causal risk
factor
Clinical effectiveness: LDLC-
targeted treatment reduces
risk
Not dependent on TG
variability
Can always be calculated
in the nonfasting state
Includes remnant
cholesterol
Unequivocally deﬁned protein
International standard available
Analytical performance: fasting and
nonfasting test accuracy
Fully automated test; can be easily
integrated in widely available
laboratory autoanalyzer platforms
Diagnostic performance for
characterization of complex, mixed
dyslipidemias
Measures LDL particle
number and size
Often provides simultaneous
quantiﬁcation of VLDL,
IDL, LDL, HDL particle
numbers and size, and in
some cases other
metabolic or inﬂammatory
biomarkers, in 1 single run
of the assay
Weaknesses
dLDLC measurement errors in
dyslipidemic samples and
samples from diseased
patients
cLDLC inﬂuenced by HDLC
measurement errors
cLDLC inﬂuenced by
postprandial TG variability;
invalid at TG >400 mg/dL
(4.5 mmol/L)
cLDLC and dLDLC inﬂuenced
by increased Lp(a)
Manufacturer-dependent
nonspeciﬁcity bias
compared with reference
method
HDLC measurement
errors in dyslipidemic
samples
Different assays for
HDLC affect between-
laboratory
measurement
variability
Arbitrary risk cutpoints
and treatment targets,
not validated for
clinical performance
Controversial clinical performance vs
LDLC and non-HDLC for risk
estimation in general populations
due to high correlations with TC
and LDLC
Arbitrary risk cutpoints and
treatment targets
No consistent evidence of signiﬁcant
population health-economic
beneﬁt of intensiﬁed or novel
therapies aiming to reduce apoB
No standardization
Inconsistent agreement
between different
methods
Expensive and/or not widely
available technology
Not easily integrated in high-
throughput laboratory
operations
Opportunities
Novel therapies appear to
safely reduce LDLC to very
low concentrations (long-
term follow-up is limited)
Novel therapies conﬁrm the
LDL hypothesis “the lower
the better”
Increasing awareness and
demand to screen for familial
hypercholesterolemia
Improved cLDLC equations
published
Healthcare budget: no
additional cost
Increasing use of
nonfasting blood
samples
Additional risk
reclassiﬁcation by
discordance analysis
vs LDLC
Clinical utility particularly
when LDLC is low or
TGs are increased
(needs to be
validated)
Increasing prevalence of obesity,
diabetes, and atherogenic
dyslipidemias with increased apoB
Additional risk reclassiﬁcation by
discordance analysis vs LDLC (and
in some studies vs non-HDLC)
Clinical utility particularly when LDLC
is low or TGs are increased (needs
to be validated)
Emerging mass spectrometry
applications in the clinical
laboratories, enabling more
precise and multiplex
apolipoprotein tests
Increasing prevalence of
atherogenic dyslipidemias
with increased LDLP and
VLDLP
Additional risk
reclassiﬁcation by
discordance analysis vs
LDLC
Emerging evidence of cost-
effectiveness by
metaanalyses
Automated NMR assays are
being developed
Threats
Residual on-treatment CVD
risk, not explained by LDLC
Increasing prevalence of
obesity, diabetes, and
atherogenic dyslipidemia, in
which LDLC is less predictive
Uncertain analytical
performance at very low
concentrations obtained with
novel therapies
No conceptual
understanding by
most practicing
physicians and
patients
Potential increases in estimated
healthcare costs
Poor goal attainment rates on statin
therapies, including high-dose
statins
No conceptual understanding by
most practicing physicians and
patients
Assays not widely available
in clinical laboratories
No conceptual
understanding by most
practicing physicians and
patients
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proteins (Table 2). EQA programs, which structurally
evaluate laboratory test performance, demonstrate that
improvements are necessary (47, 48 ). New therapies de-
mand accuracy of dyslipidemia testing at very low LDLC
concentration ranges. Incorrect diagnosis and misman-
agement of treatment, which are based on laboratory
measures, are both costly to society and harmful to the
patient. Evenmodest improvements in laboratory testing
to predict risk of a disease as common as CVD translate
into thousands of people who may be treated more ap-
propriately and could benefit. Therefore, it is essential
that diagnostic test results produced in laboratories
worldwide are comparable across different medical facil-
ities, enabling unequivocal diagnosis, treatment, and
monitoring of patients. This prerequisite is increasingly
recognized by European Conformity (CE) marking and
Food andDrug Administration regulatory bodies in their
patient-focused risk assessment during premarket ap-
proval of in vitro diagnostic medical devices (136 ). To
that end, global standardization and harmonization of
lipid tests should be the key for sustainable patient care
with universal application of desirable values and de-
cision cutpoints, as well as preparing for future ex-
change and interoperability of electronic health re-
cords (142, 143 ).
Some questions remain unanswered and need fur-
ther investigation (Table 8). In hypertriglyceridemic pa-
tients, several analytical and clinical performance limita-
tions make LDLC an unreliable marker of atherogenic
dyslipidemia; hence, there is a possibility of undertreat-
ment. ApoB has the potential to be standardized across
laboratories, which is not possible for LDLC and non-
HDLC with the current CDC standardization program.
Non-HDLC and apoB have the potential to address clin-
ical needs unmet with LDLC testing, and they can always
be used in nonfasting samples. To combine the strengths
and to compensate for the weaknesses of the different
markers, currently it seems the best strategy to consider is
the use of LDLC, non-HDLC, and apoB as complemen-
tary rather than competitive markers of CVD risk and
therapeutic response. Nonfasting non-HDLC can be
used to assess the incremental risk of remnant lipopro-
teins, and apoB can detect increased LDLP often missed
with LDLC alone. This suggestion is consistent with sev-
eral guidelines and consensus documents that propose to
use non-HDLC or apoB as a secondary treatment target
in the treatment of high-risk or very high-risk patients
with mild to moderate hypertriglyceridemia, defined as 2
to 10 mmol/L (175–880 mg/dL) (CBR8) (14 ). If the
primary target LDLC is at goal but non-HDLC or apoB
Table 7. Contemporary evidence for the medical use of LDLC, non-HDLC, apoB, and LDLP as biomarkers based
on essential criteria.
Test characteristics LDLC Non-HDLC ApoB LDLP
Analytical performancea
Precise assays Yes Yes Yes Yes
Accurate assays (method independency) No No Yes No
Nonfasting measurement possible With TG <4.5 mmol/L Yes Yes Yes
Widely accessible assays Yes Yes Yes No
High throughput and rapid turnaround Yes Yes Yes Yes
Reasonable operational costs Yes No extra cost Yes Not yet
Clinical performanceb
Robust associations with incident CVD? Yes Yes Yes Yes
Novel information beyond existing markers? (Reference) Yes Yes Yes
Validated decision limits? No No No No
Clinical effectivenessc
Superiority to existing tests? (Reference) Probably Probably Probably
Modiﬁable risk association (treatment target)? Yes Yes Yes Yes
Biomarker-guided treatment reduces CVD risk? Yes Probably Probably Unknown
Cost-effectivenessd
Biomarker-guided treatment saves healthcare costs? Yes Unknown Unknown Unknown
a Analytical validity: ability of the test to conform to predeﬁned quality speciﬁcations to measure the marker of interest.
b Diagnostic or prognostic accuracy: ability of the test to consistently detect patients with a high risk for developing CVD.
c Clinical utility: ability of the test to improve health outcomes of the patient under standard clinical care.
d Health-economic advantage of introducing the test in medical practice (value for money).
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is still high, attainment of all 3 targets will require inten-
sified lipid-lowering therapy, lifestyle (re)inforcement,
and/or additional TG-lowering drugs (e.g., fibrate or
omega-3 fatty acids) (1 ).
Which of the biomarkers to choose as secondary
target: non-HDLC or apoB? To help train clinicians and
patients in gaining an understanding of the concept and
advantage of apoB (or LDLP) testing beyond LDLC, we
need to gently transition into this process. To that end, as
a first step we should move to include non-HDLC into
the report of every lipid profile. Diabetes and abdominal
obesity, the disorders that underlie the clinical expression
of polygenic hypertriglyceridemia, are attaining epidemic
proportions (14 ); hence, apoB and LDLP tests will likely
become more and more useful in the future. This under-
scores the need to standardize and harmonize innovative
biomarkers such as NMR-based lipoprotein particles
or LC-MS/MS proteomics, which have the potential
to become innovative medical tests. To be prepared for
the future of personalized medicine, obviously the
most important challenge of apoB is to validate its use
as part of a multiplex MS/MS-based apolipoprotein
profile rather than a single marker test. These technol-
ogies provide complementary clinical information re-
garding the complex molecular basis of polygenic hy-
pertriglyceridemias and, as such, will contribute by
identifying better and individualized treatment op-
tions for dyslipidemic patients.
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EAS-EFLM Joint Consensus Panel members were nominated by EAS,
EFLM and the co-chairs M.R. Langlois and B.G. Nordestgaard to
represent expertise across clinical and laboratory management and lipid
research from across the World. The Panel met twice, organized and
chaired by M.R. Langlois and B.G. Nordestgaard. The first meeting
Table 8 Unanswered questions and recommendations for future research.
Unanswered questions (Q)
Q1 Which (measured or calculated) LDLC method provides the best proxy for the gold standard
measurement (ultracentrifugation) to ensure adequate translation of LDLC test results to the
atherogenic risk of “true” LDL particles?
Q2 Are guideline-recommended LDLC and non-HDLC goals used in clinical practice (based on
Friedewald-cLDLC and non-HDLC calculations in study populations using the older HDLC
precipitation methods) still applicable to LDLC and non-HDLC values as currently reported (i.e., as
measured or calculated using contemporary assays)?
Q3 Can follow-up of lipid-lowering therapies be simpliﬁed using a single-marker, nonfasting apoB assay to
replace the traditional lipid proﬁle to obtain at least equal, or even better, assessment of
dyslipidemia-related risk?
Q4 Can multimarker test panels of apolipoproteins and/or lipoprotein particles and subclasses provide
precision medicine-individualized assessment of dyslipidemia-related risk in the patient?
Future research
(FR) action points
to address the
above questions
FR1 Assay kit manufacturers and standardization programs should be closely linked to optimize the assays,
or select only 1 best possible chemical procedure and type of assay, to ensure accurate and
unequivocal measurements of LDLC and HDLC, including low concentrations, in the fasting and
nonfasting state in both normotriglyceridemic and hypertriglyceridemic blood samples (Q1)
FR2 New generation assays should be validated for clinical performance to discriminate between high- and
low-risk patients, e.g., by reporting risk reclassiﬁcation in observational studies using the net
reclassiﬁcation index (Q2)
FR3 Clinical and cost-effectiveness studies should be designed to determine the health outcomes and
economic implications of apoB-based treatment of high-risk patients (or subgroups of patients),
relative to the standard care of LDLC management (Q3)
FR4 NMR-based lipoprotein particle/subclass numbers and size measurement procedures should be
standardized to ensure direct comparability of NMR data for the development of universally
applicable guidelines and decision cutpoints (Q4)
FR5 Multiplex LC-MS/MS apolipoprotein proﬁles (including apoA-I, B, C-I, C-II, C-III, and E) rather than
single apoB tests should be further developed, standardized, and evaluated for the creation of a
personalized clinical pathway: clariﬁcation of unmet clinical need(s) and diagnostic accuracy to
identify the dyslipidemias of interest (Q4)
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critically reviewed the literature while the second meeting reviewed
additional literature and scrutinized the first draft of the joint con-
sensus statement. The recommendations should be considered as
consensus-based because evidence was not always available or incon-
sistent. All Panel members agreed to conception and design, con-
tributed to interpretation of available data, all suggested revisions
for this document, and all members approved the final document
before submission.
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